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ABSTRACT
Antibodies are higher order protein structures produced by a subset of lymphocytes (B
cells) in the immune system for protection against pathogenic species. These homodimers of
heterodimers form highly specific interactions with their cognate antigens and hence have
become very important for the development of prophylactic or therapeutic agents against
different disease pathogens. A key step in the development of human monoclonal antibodies as
therapeutics is identification of candidate antibodies either by direct screening of human
antibody repertoires or by filtering through combinatorial libraries of human variable genes using
display technologies. Combinatorial libraries of human variable genes afford the flexibility to
pursue many targets of interest, but often result in the selection of low affinity antibodies or
unnatural heavy and light chain pairings that would have been selected against in vivo. With
direct screening of the human B cell repertoire, the challenge is how to efficiently isolate clones
of interest. Presented in this thesis is a high-throughput, integrated, single-cell methodology
based on microengraving that allows the rapid recovery of antigen-specific human B cells.
Microengraving is an analytical technique wherein secreted molecules from individual
cells seeded into a dense array of subnanoliter wells are captured on the surface of a glass slide,
generating a microarray from which desirable cells can be identified and recovered. Combined
with high resolution epifluorescence microscopy and single-cell RT-PCR, we have developed
assays for the simultaneous profiling of surface-expressed phenotypes of primary antibody-
producing cells, as well as functional characteristics of their secreted antibodies and germline
variable gene usage. Using clinical samples from HIV- and West Nile virus-infected subjects, we
demonstrate that the method can identify antigen-specific neutralizing antibodies from both
plasmablast/ plasma cell and memory B cell populations, and is ideal for the detailed
characterization of cells from anatomical sites where sample sizes are often limited and disease
pathophysiology is poorly understood (e,g. gut tissue, bone marrow).
Thesis Supervisor: J. Christopher Love
Title: Latham Family Career Development Associate Professor
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CHAPTER 1: INTRODUCTION
1.1. B cell immunology and antibody development
The immune system is a complex network of cells and proteins that interact and work in
concert to protect the body from pathogenic species (e.g. bacteria, fungi, viruses, protozoa,
cancerous cells, etc.) that cause disease. The innate arm of the immune system serves as the first
line of defense against pathogens and is characterized by breadth - being capable of recognizing
a wide range of species with limited specificity. The second arm of the immune system, the
adaptive immune system, comprises both cell-mediated and humoral responses (T cell and B cell
based responses, respectively) that are highly specific and able to generate immunological
memory for rapid recall responses upon secondary exposure to the same antigens. Along with
functioning as antigen-presenting cells (APCs), B cells are primarily responsible for the
production of immunoglobulins (Igs) or antibodies [1]. Antibodies are soluble or surface-bound
receptors that recognize specific structural or peptide motifs (epitopes) on the surface of antigens,
allowing the neutralization, agglutination or opsonization of these targets. Antibodies are also
able to induce effector functions from effector molecules and cytolytic cells by complement
activation and antibody-dependent cell-mediated cytotoxicty (ADCC), respectively, initiating the
destruction of infected cells.
Upon the encounter of a cognate antigen, naYve B cells undergo affinity maturation in
germinal centers of lymphoid tissues, followed by clonal expansion, and finally differentiation
into actively-secreting plasma cells or resting memory B cells. Plasma cells either remain in
lymphoid tissues or home to the bone marrow and continuously secrete large quantities of
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antibody [1, 2]. Memory B cells, on the other hand, home to other tissues awaiting subsequent
encounter of the cognate antigen. Although long-lived plasma cells exist in the bone marrow,
most plasma cells raised in response to an infection are short-lived [2], hence the analysis of this
population only provides an instantaneous snapshot of the humoral immune response to an
infection. Memory B cells persist throughout the life of an individual, documenting the
evolutionary history of B cells selected for during the course of an infection. Interestingly, some
evidence suggests a discrepancy in the repertoire of antibodies secreted by plasma and memory
B cell populations in response to a particular antigen [3], but the extent to which these repertoires
differ has yet to be explored on a cellular basis.
The sequence of amino acids in the variable regions of the heavy and light chains dictates
the specificity of an antibody. The large number of V, D and J (V and J only, for light chains)
gene segments in the human chromosome that can be combinatorially assembled during B cell
development, and extra nucleotide additions during recombination, provide sufficient diversity to
enable the generation of antibodies capable of recognizing any antigen [4, 5]. Affinity maturation
by clonal selection and somatic hypermutation driven by the presence of antigen further
improves the quality of antibodies produced, selecting for clones with increased affinity. During
the acute phase of an infection or following vaccination, high-affinity antibodies recognizing
epitopes displayed by immunogenic species are predominant. The isolation of such antibodies
can be readily accomplished with existing technologies for antibody discovery [6, 7]. For chronic
conditions such as type 1 diabetes or infection by the human immunodeficiency virus type 1
(HIV-1), however, the frequency of B cells producing functional antigen-specific antibodies is
relatively low, making the recovery of such cells for detailed characterization a challenging
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process [8, 9]. There has, therefore, been a need for new analytical tools with the sensitivity to
permit access to these unique populations of cells.
1.2. Existing tools for B cell analysis
Given the successful use of antibodies in polyclonal antiserum as prophylactics and more
recent success at the use of monoclonal antibodies to treat a variety of cancers, inflammatory
conditions, infectious and autoimmune diseases [10-12], there is interest in understanding how
the humoral immune response evolves to produce such effective antibodies, and in identifying
candidate antibodies for the design of therapeutic agents or immunogens in vaccines. Traditional
strategies for the discovery of B cells producing antigen-specific antibodies have relied on the
use of the enzyme-linked immunosorbent assay (ELISA) [13, 14], enzyme-linked
immunosorbent spot (ELISPOT) assay [15-17], flow cytometry [6, 18] or the mining of libraries
of variable genes using display and expression technologies or novel bioinformatic analysis tools
[4, 19-21].
In an ELISA, supernatants are incubated over a capture surface coated with antigen or a
capture reagent specific for the analyte of interest. Secondary antibodies are used to detect bound
analyte, which can be read and quantified by fluorescence. ELISA is sensitive but requires
culturing of source cells to obtain detectable levels of Ig in supernatant. The ELISPOT assay is
very similar to the ELISA. Dilutions of cells are incubated on a capture substrate, and secreted
products (e.g. antibodies, cytokines) are captured then detected as "spots" of signal where
antigen-specific cells were originally deposited. The technique is highly sensitive - able to detect
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1 in 105-106 events - but only suitable for conveniently measuring at most two analytes per cell
[22, 23]. Also, source cells are lost and cannot be recovered for subsequent analysis.
Analysis by flow cytometry has been significant in informing our current knowledge of
immunology by allowing the simultaneous detection of tens of parameters [24, 25].
Fluorescence-activated cell sorting (FACS) has also made it possible to rapidly isolate unique
cells from heterogeneous populations of cells, and is a cornerstone of several display
technologies [6, 26-29]. A necessary feature for flow cytometric analysis is the expression of
analytes of interest on the surface of source cells. This linkage between genotype and phenotype,
unfortunately, has limited much of the discovery of antigen-specific B cells to searching the
repertoire of memory B cells, as plasma cells only express a secreted form of Ig. The
indiscriminate sorting of plasma cells or plasmablasts during acute infection or following a
vaccination does provide access to native human antibodies among this population [6, 7, 30], but
can be inefficient when antigen-specific cells represent a minor fraction of the population [9].
Moreover, with this technology, the lower limit for detection of rare events is on the order of 1 in
103-104 events [31, 32], therefore, more cells are required to accurately identify clones of interest.
Combinatorial libraries of human variable genes afford the flexibility to pursue any target of
interest, but often result in the selection of low affinity antibodies or unnatural heavy and light
chain pairings that would have been selected against in vivo [4].
Newer technologies for the analysis of B cells and their secreted antibodies [33-35] have
focused on reducing the form-factor required for culture and/or analysis, as the volumes required
for analysis would be smaller and very high concentrations of Ig can be accumulated in short
16
periods of time. The ELISPOT-like immunospot array assay on a chip (ISAAC), for instance,
has facilitated the recovery of antigen-specific actively secreting cells (ASCs) from recently
vaccinated subjects [34]. In this work, the microengraving approach [36] was expanded to enable
the profiling of different B cell subsets in samples from human subjects.
1.3. Microengraving
Microengraving is a high-throughput, soft lithographic technique in which an array of
~105 sub-nanoliter wells (nanowells) is used to partition and culture a heterogeneous population
of cells as single-cell isolates. The supernatant from each nanowell, containing the secreted
molecules (e.g. antibodies, cytokines, etc.) of cells confined within each nanowell, can then be
transferred or "engraved" onto the surface of a functionalized glass slide (Figure 1.1), in a
manner similar to intaglio printing [37]. This process generates protein microarrays detailing the
secretion profile of each cell, with elements on the protein microarrays mapping directly to
particular well-locations in the corresponding array of nanowells. The method is versatile,
allowing the rapid profiling of different cell types (e.g. hybridomas, peripheral lymphocytes,
yeast, etc.), in a compact, micrometer-scale form factor [35, 36, 38-41]. With this technique, one
can simultaneously examine the phenotype and functionality of single cells, allowing the study
of heterogeneous cell populations in a way unavailable in the generally accepted immunoassay
formats of a 96-well microtiter plate or flow cytometer; especially when the sample-size is
limited.
A distinct advantage of the microengraving approach is the ability to separate cells from
the detection medium and/or surface, as baits may interact directly with the surface of cells,
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increasing the number of false positives. This feature also allows for repeated analysis and
multiplexing beyond what has been achieved with other techniques. In addition, cells of interest
can be recovered and expanded in culture, or genetic material can be recovered for cloning,
indicating that the technology would be applicable for the analysis of both memory and actively-
secreting B lymphocyte populations. Plasma cells have low survivability ex vivo, hence studies
of antigen-specific B cells to date have focused largely on the analysis of the more stable
memory repertoires. With this technique, however, detailed analyses of antigen-specific plasma
cells and their secreted products can be performed in a short period of time (~1-2 h), obviating
the need for extended culture. Therefore, with micoengraving, it is feasible to study these
terminally-differentiated ASCs essential for the observed humoral response to an infection in
vivo.
1.4. Specific aims and outline of dissertation
Broadly, the objectives of this thesis were to establish techniques with clinical relevance
that would enable comprehensive functional characterization of antibodies in a single assay,
ideally from primary human B cells. The importance of such technologies in the context of
infectious diseases would be to streamline the processes involved in the discovery of antibodies
with desirable functionalities, and to significantly improve the efficiency with which researchers
can perform the necessary analyses, in terms of cost, time and yield. Using microengraving
technology, the specific goals for my doctoral thesis were as follows:
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1. Establish protocols for the handling of actively-secreting cells and memory B cells ex
vivo, along with methods for the processing of cells identified as expressing unique
phenotypic traits.
2. Develop analytical tools for the detailed evaluation of multiple functionalities of
antibodies produced by primary B cells, in an efficient and high throughput manner.
3. Characterize B cells of the plasma and memory cell repertoires in different lymphoid
tissues, and in patients at different stages of infection, to reveal the intricacies of the
humoral response to infection and to enable the construction of antibody-based disease-
state profiles.
Chapter 2 of this dissertation outlines the materials and methods used in the experiments
involved in establishing and validating assays for B cell analysis. A detailed description of the
development and optimization of key steps in the assays is provided in Chapter 3. Chapters 4 and
5 describe studies exploring the effects of infectious diseases - HIV-1 and West Nile virus
(WNV) infections, respectively - on the humoral immune repertoire, taking advantage of new
improvements in the microengraving platform. Finally, a summary of all results generated in the
course of this thesis, and a discussion of the significant conclusions drawn from this work are
provided in Chapter 6.
19
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Figure 1.1: Schematic of the microengraving process for isolation of functional B cells
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CHAPTER 2: MATERIALS AND METHODS
2.1. Ethics statement
Patient samples were obtained following approval by the institutional review boards at
Massachusetts General Hospital (MGH), Boston; Massachusetts Institute of Technology (MIT),
Cambridge; Brigham and Women's Hospital (BWH), Boston; and the Yale School of Medicine,
New Haven. Written informed consent was obtained from study participants prior to enrollment
in studies.
2.2. Peripheral blood and mucosal tissue samples
Blood and intestinal biopsies were collected from HIV-infected individuals from a cohort
of controllers (HIV-1 viral load < 2,000 RNA copies/mL in the absence of HAART) and
progressors (HIV-1 viral loads > 2,000 RNA copies/mL in the absence of HAART, or HIV-1
viral loads < 50 RNA copies/mL on fully suppressive HAART) from MGH [42]. Peripheral
blood mononuclear cells (PBMCs) from blood samples were isolated using Histopaque@-1077
(Sigma-Aldrich). Cells were then either analyzed fresh or from frozen aliquots of 107 cells.
Intestinal biopsies were obtained by upper and lower endoscopy. Tissue was disaggregated using
both mechanical disruption and enzymatic digestion, based on published protocols [43]. Briefly,
biopsied samples were resuspended in RPMI 1640 supplemented with 10% (v/v) fetal calf serum
(FCS), L-glutamine, piperacillin/tazobactam (250 ptg/ml), amphotericin B (1.25 tg/ml) and
collagenase II (0.5 mg/ml; Sigma-Aldrich). Tissue was incubated for 30 min with constant
agitation (370C, 5% C0 2). The supernatant was collected and passed through a 75- im cell
strainer. The remaining tissue pieces were passed through a 16G blunt needle and then subjected
to another round of collagenase digestion. This process was repeated twice. Finally, cells were
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washed in media and maintained at 37'C (5% CO2) until used. PBMCs from healthy donors were
obtained from BWH or purchased from SeraCare Life Sciences Inc. (Milford, MA). Before
screening populations of ASCs, PBMCs were thawed and rested for 1 h in complete media
(RPMI 1640 media supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin
and 100 ptg/mL streptomycin; 37 0C, 5% CO 2).
2.3. Activation of memory B cells
A mixture of stimulatory molecules based on previous reports for polyclonal activation of
B cells [44-51] was used to induce antibody secretion by resting memory B cells. ~3 x 106
PBMCs were seeded in 5 mL round-bottom tubes (BD Falcon) and incubated for 3-7 days in 500
ptL of complete media, containing combinations of antibodies, cytokines, toll-like receptor (TLR)
agonists and mitogenic species. Additional information is included in Section 3.3.
2.4. Antibody-producing cell lines
12CA5 mouse hybridoma cells, secreting antibodies against hemagglutinin (HA; ATCC)
were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco), supplemented with 10%
inactivated fetal calf serum (IFS), 20 mM HEPES (Gibco), 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids (Gibco), 100 units/ml penicillin, 100 ptg/ml streptomycin, 50 pM 2-
mercaptoethanol and 5 mM L-glutamine. HYB099-01 mouse hybridoma cells, secreting
antibodies against ovalbumin (OVA; Statens Serum Institut), were also cultured in the same
media except that IFS was substituted with 10% fetal bovine serum (FBS; PAA). A human B cell
hybridoma cell line producing the 4D20 (anti-HA) antibody [14] (courtesy of J. Crowe,
Vanderbilt University) was adapted to grow in RPMI 1640 media with 15% (v/v) FBS, 2 mM L-
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glutamine and 1 mM sodium pyruvate. Lastly, Chinese hamster ovary (CHO) cell lines
producing b12, b6 (anti-gp120) and 2F5 (anti-gp41) antibodies (courtesy of D. Burton, Scripps
Institute) were cultured in ProCHO-5 media (Lonza) with 3% FBS, 1 x HT supplement (Gibco),
1x GS supplement (Sigma-Aldrich), 100 U/mL penicillin, 100 tg/mL streptomycin and 50 [tM
L-methionine sulfoxime (Sigma-Aldrich).
Cell lines were cultured at 37 'C (5% CO 2), and maintained at a density of 105-106
cells/mL by passaging into fresh media every 3-5 days. Cells were used in experiments when
cultures were 70-80% confluent.
2.5. Microengraving
2.5.1. Fabrication of arrays of nanowells
Arrays with ~80,000-250,000 wells (50 x 50 x 50 pm 3 or 30 x 30 x 30 11m 3 in dimension,
respectively) were fabricated by molding polydimethylsiloxane (PDMS; Sylgard 184) on silicon
wafers patterned with SU-8 by photolithography. Arrays were designed with a dense
arrangement of 7 x 7 or 12 x 12 wells (for 50- or 30-tm well dimensions, respectively) in a
block of wells. Each block was equivalent in size to the field-of-view on an EM-CCD camera
(Hamamatsu). Blocks were arranged in a rectangular grid of 24 columns and 72 rows to make
the arrays compatible with 25 mm x 60 mm coverslips and 25 mm x 75 mm glass slides. 50 ptm
microchannels further partitioned the array into groups of 4 x 4 blocks to simplify subsequent
analyses and facilitate drainage of media during the microengraving process [52]. PDMS
prepolymer was generated by mixing elastomer base and curing agent in a 10:1 (base:curing
agent) ratio by weight. Air bubbles were removed from the mixture by incubation under vacuum
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at room temperature for 1 h. Degassed prepolymer was injected into custom-made molds, and
then cured for 2-3 h at 80 "C. After curing, arrays were removed, covered and stored at ambient
conditions until used. Arrays were treated with oxygen plasma (PDC-001, Harrick Plasma)
immediately prior to use and then placed into sterile phosphate buffered saline (PBS).
2.5.2. Preparation of capture slides
3"x1" glass slides (Coming) were cleaned in a mixture of 2.5M NaOH and 60% (v/v)
ethanol, washed thoroughly in deionized water, and then submerged in 0.001% (v/v) poly-L-
lysine (Sigma-Aldrich) with 0.1 x PBS for 2 h. After incubation, slides were washed, dried and
stored in a dessicator at room temperature until used. To generate surfaces to capture secreted
antibodies, poly-L-lysine functionalized glass slides were incubated overnight with a polyclonal
donkey anti-human (H+L) capture antibody (25 ptg/mL, Jackson Immunoresearch) in a borate
buffer solution (50 mM sodium borate, 80 mM sucrose and 50 mM NaCl, pH 9) under a
LifterSlip M at 40C. Steps for processing slides before and after capture of secreted antibodies
have been previously reported [52]. Briefly, slides were placed in a solution of PBS containing
nonfat milk (3% w/v) and Tween-20 (0.05% v/v) for 15 min at room temperature with mild
agitation. Slides were then rinsed twice with a solution of PBS and Tween-20 (0.05% v/v),
followed by PBS and water, and finally spun dry.
2.5.3. Distribution of cells into arrays of nanowells
Cells were deposited onto treated arrays of nanowells at a density of ~2 x 105 cells/mL
and allowed to settle into wells for 5 min, under gravity. A Poisson distribution of cells was
typically observed, with ~30% of wells occupied by single cells when loading 1 x 105 cells onto
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an array with 50-tm wells. Higher loading densities were achieved by repeating this process
until desired well occupancies were observed. For the analysis of primary B cells, PBMCs were
deposited onto an array of nanowells to obtain a density of ~3-5 cells/well. Given that these cells
constitute only ~5% of total PBMCs, each occupied well at this density holds one B cell on
average. Excess cells were gently rinsed from the top of each array with complete media and
then removed by aspiration. Arrays were submerged in complete media until imaging or
microengraving steps.
2.5.4. Printing and interrogation of microarrays
Arrays of nanowells loaded with cells were sealed with capture slides and incubated
together for 2 h (370C, 5% C0 2). The assembly was held under compression using commercial
hybridization chambers (G2534A, Agilent). The resulting microarrays of antibodies were panned
with solutions of antigens diluted in PBS with 0.1% (w/v) bovine serum albumin (BSA). Bound
antigen was detected with either secondary detection antibodies or direct conjugation of antigen
with fluorescent species. A mixture of mouse anti-human Ig detection antibodies (anti-IgGI,
clone JDC-1; anti-IgAl/2, clone G18-1; anti-IgG3, clone HP6050; and anti-IgM, clone G20-127),
each at 1 [tg/mL and diluted in PBS with 0.1% (w/v) BSA and 0.05% (v/v) Tween-20 was used
to indicate the presence of Ig isotypes. Ig detection antibodies were purchased unconjugated
from BD or Invitrogen and fluorescently labeled with Alexa Fluor* protein labeling kits
(Invitrogen). Details of ideal channel combinations are given in Section 3.1. Slides were scanned
on a GenePix® 4200AL microarray scanner (Molecular Devices) to register the information
captured.
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2.5.5. Analysis of printed microarrays
GenePix Pro 6.0 (Molecular Devices) software was used for analysis of acquired
microarrays. A custom GenePix Array List (GAL) template, with blocks of spots designed to
match blocks of wells within the array, was used to determine the location of cells secreting
antibodies of interest. The template assigned each element a unique identifier or well ID,
corresponding to the location of source cells in the array of nanowells. Alignment of the template
over images was done manually. Alignments and re-orientation were performed using signal
from the fluorescent channel with the highest frequency of events. After alignment, local
background-corrected median fluorescent intensities (MFIs) were extracted for each element;
these data were then sorted to identify elements of interest, and exported into a comma-delimited
text file. Printed elements in the arrays were considered Ig* with % saturation < 2, signal-to-noise
ratio > 1, > 40% of pixels above background + 1 standard deviation and CV < 200, and after
compensation for bleed-through of signal from adjacent channels. All antigen-specific events
were also confirmed by visual inspection since they were typically < 10% of all Ig* events. More
stringent criteria [52] were applied for the analysis of data from experiments with cell lines given
the narrower distribution of intensities typically observed and the significantly larger fraction of
elements with background-corrected MFIs > 10,000.
2.5.6. Spot assay
The spot assay is a cell-free assay designed to mimic the microengraving process that was
used for validation of reagents and/or determination of optimal reagent concentrations for
microarray analysis. Dilutions of standards or control antibodies in buffered solutions were
spotted manually (~2 pL) on capture slides and incubated at 370C in a humidified chamber for a
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period of 1 h. Residual drops were aspirated, then slides were blocked and washed as previously
described. Microarrays were incubated with detection species (fluorescently-labeled antigen or
detection antibodies), scanned on GenePix* 4200AL and analyzed with GenePix Pro 6.0.
2.6. Cytometry
PBMCs were stained for viability and surface-expressed proteins with CellTraceTM
Calcein Violet AM and a panel of mouse anti-human antibodies - anti-CD19 (clone SJ25-C1,
Qdot® 605/Brilliant VioletTM 605 conjugate), anti-CD20 (clone 2H7, Alexa Fluor* 488
conjugate), anti-CD27 (clone 0323, PE-Cy7 conjugate), anti-CD38 (clone HB7, PerCP-eFluor*
710 conjugate), and anti-CD138 (clone B-B4, APC conjugate), using manufacturers'
recommended concentrations. Cell lines were stained with CellTraceTM Calcein Violet AM
(Invitrogen), Calcein AM (Invitrogen), CellTracker m Red (Invitrogen) or TFL4 (Oncolmmunin,
Inc.) viability dyes to enable capture of nanowell occupancies. Cells were labeled for 30 min at
room temperature in complete media. Flow cytometry was performed on BDM LSR II or BD
LSRFortessal cell analyzers available at the Swanson Biotechnology Center (Koch Institute)
and data was analyzed using FlowJo Version 9.6.1 (TreeStar, Inc.). For on-chip cytometry,
labeled cells were loaded onto arrays of nanowells, washed with PBS containing 2% (v/v) FBS,
and covered with a LifterSlip TM (EMS). Transmitted-light and fluorescent images were then
acquired on an automated epifluoresence microscope (Carl Zeiss) fit with an EM-CCD camera
(Hamamatsu). The images were analyzed on a block-by-block basis using custom software [39]
to determine the viability and the level of expression for each marker. Data were gated first for
size then mean fluorescence intensities were extracted for the different fluorescent channels.
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2.7. Retrieval of cells from nanowells
Cells were recovered from arrays using an automated micromanipulator (CellCelector,
ALS GmbH). Cells were retrieved for either clonal expansion or recovery of antibody genes. For
clonal expansion, arrays with cells were immobilized in 4-well plates and submerged with
complete media. The individual steps required for the transfer of a cell from a nanowell to a well
in a 96-well plate, in order, were: (1) pre-aspiration of media from the reservoir; (2) aspiration of
the cell(s) from the targeted nanowell, and (3) deposition of the picked cell(s) into the well of a
96-well plate filled with 200 pL pre-warmed complete media (37'C). Plates of cells were then
returned to an incubator and maintained at 37 0C (5% C0 2). For the recovery of heavy and light
chain genes, arrays of nanowells were stored at 4'C in complete media until cells were to be
recovered. Capillary tips used for recovery were first sterilized with RNaseZap* (Invitrogen),
washed thoroughly with nuclease-free water then blocked with Salmon Sperm DNA (1 mg/ml,
Ambion) to minimize spurious contamination by nucleic acid. Arrays were immobilized in 4-
well plates and gently washed, then submerged in PBS to remove residual media, which can
interfere with gene amplification. Target cells were picked directly and were deposited in wells
of a 96-well PCR plate with 20 ptL 1x First-Strand Buffer (Invitrogen) and 10 U RNasin*
(Promega). After recovery, plates of cells were typically frozen and stored at -80'C until reverse
transcription polymerase chain reactions (RT-PCRs) were performed.
2.8. Amplification of variable genes
Amplification of antibody genes was carried out in four steps: Cell lysis, cDNA synthesis,
PCR I and PCR II. For cell lysis, 1.25% (v/v) Nonidet@ P-40 (G-biosciences) and 150 ng
random hexamers were added to each reaction, and then samples were heated to induce lysis
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(65'C, 10 min; 25'C, 3 min). 1 OOU Superscript* III reverse transcriptase (Invitrogen), 2 [IL 5x
First-Strand Buffer (Invitrogen), 2 [pL 0.1 M DTT (Invitrogen) and 1 [L 2.5 mM dNTP were
added for cDNA synthesis (370C, 1 h). First PCR was then run with HotStar* Taq DNA
polymerase (Qiagen) in a total reaction volume of 50 [L (-5 [IL template, 5 [L 10 x buffer, 2 [pL
2.5 mM dNTP, 0.5 [IL forward and reverse primer mixes, 0.25 [IL HotStar* Taq). After
activation of the polymerase at 95'C (6 min), 3 cycles of pre-amplification were carried out
{94 0C (45 s), 45'C (45 s), 72'C (45 s)}, followed by 30 cycles of amplification {940C (45 s),
500C (45 s), 72'C (1 min 45 s)}, and a final extension at 720C (10 min). For PCR II, a nested
PCR was run with cloned Pfu polymerase (Agilent), also in a total reaction volume of 50 [pL (~3
[IL template, 5 [IL lOx buffer, 1.25 [IL 2.5mM dNTP, 1 [IL forward and reverse primer mixes,
0.5 [IL Pfu). 30 cycles of amplification were used {940 C (45 s), 500C (45 s), 72 0C (1 min 45 s)},
with a final extension at 72'C (10 min). To improve the overall yield in amplification, restriction
sites were eliminated from primers for the nested PCR. A complete list of all primers used is
included in the Appendix (Table A. 1)
2.9. Cloning and expression of monoclonal antibodies
Paired heavy and light chain genes were cloned into vectors for expression as human
IgG1 (courtesy of M. Nussenzweig, Rockefeller University), based on a published protocol [53].
Appropriate restriction sites for expression vectors were introduced with another round of PCR
using primers from Tiller et al. [53]. Products were purified with QIAQuick PCR Purification kit
(Qiagen), digested, and ligated into Igyl, IgK, or Igk vectors (50 ng) using T4 DNA ligase (NEB).
Plasmids were then transformed into chemically competent NEB5a E. coli (NEB). Colonies
were screened by PCR using 3IgVs-PCR-fwd (5'-CACTTTGCCTTTCTCTCCACAGGT-3')
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and 3IgVs-PCR-rev (5'-ACAGATGGTTCTTTCCGCCTCAGA-3') primers. After sequence
verification, plasmids were isolated from 2-mL overnight cultures (QlAprep Spin Miniprep Kit,
Qiagen) and transiently transfected into human embryonic kidney (HEK) 293T cells (ATCC) for
antibody production. HEK 293T cells were cultured in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% (v/v) FBS, 100 U/mL penicillin and 100 [ig/mL streptomycin,
but DMEM was replaced with serum-free HL-1 T media (Lonza) just before transfections were
performed. Vectors were transfected into cells (1:1 ratio) using GenJetiM In Vitro DNA
Transfection system (SignaGen Laboratories). After 48-72 h, supernatants were recovered,
centrifuged (~450 g, 5 min), and stored with 0.02% (w/v) NaN3, at 4'C for subsequent analyses.
Despite successful recovery and sequencing, it is noteworthy that ~30% of antibodies selected
either did not clone in E.coli, or did not express as full-length human IgG1 after transfection in
the host cell line, especially with antibodies from non-IgGI isotypes.
2.10. HIV neutralization assay
Serial dilutions of purified antibodies were made in complete DMEM and distributed in
wells of a 96-well round-bottom plate (15 pL/well). 45 tL of pseudovirus (~300,000-500,000
relative luminescence units), generated by co-transfection of HEK 293T cells with an Env-
expressing plasmid and an Env-deficient genomic backbone plasmid (pSG3AEnv), was then
added to each well, and the mixture was incubated for 1 h (370C). After incubation, the mixture
was transferred onto TZM-bl cells (plated at 10,000 cell/well in a 96-well flat-bottom plate the
previous day). Cells were incubated for 24 h (370C), after which 150 pt/well of fresh complete
DMEM was added and cells were again incubated for 48 h (370C). Well contents were aspirated
and cells were lysed with 60 p.L of lysis buffer. 20 pL of lysates were transferred to a white 96-
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well flat bottom plate and 50 pL of luciferase substrate (Promega) was added to each well.
Resulting luminescence was read with a luminometer (VICTORTM X Light, Perkin Elmer). Dose
response curves generated were fit by nonlinear regression to determine 50% inhibitory
concentrations (IC 50 ) for each antibody, using signals from virus-only wells as 0% neutralization
reference.
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CHAPTER 3: ESTABLISHING PROTOCOLS FOR EX VIVO PROCESSING OF
HUMAN B CELLS
3.1. Optimization of surface capture and detection of secreted antibodies
Spot assays were used to test a variety of antibody clones specific for different constant
regions (isotypes) on human Igs to evaluate their suitability as secondary antibodies. Reagents
were optimized to enable simultaneous capture and detection of IgG1, IgAl/2, IgG3 and IgM
isotypes (Figure 3.1), all of which are known to have important effector functions in the
periphery and mucosa [1]. A polyclonal donkey anti-human Ig (H+L) antibody (Jackson
Immunoresearch) was determined to be optimal capture antibody when used at a concentration
of > 25 pg/mL. To determine the isotypes of captured antibodies, the following monoclonal
antibodies were found to work best as a panel: mouse anti-human IgGI clone JDC-1 (Alexa
Fluor* 647 conjugate, BD Pharmigen), mouse anti-human IgAl/2 clone G18-1 (Alexa Fluor*
594 conjugate, BD Pharmigen); mouse anti-human IgG3 clone HP6050 (Alexa Fluor* 555
conjugate, Invitrogen), and mouse anti-human IgM clone G20-127 (Alexa Fluor* 488 conjugate,
BD Pharmigen). Using titrations of isotype standards, it was determined that the limit of
detection for this optimized panel of capture and detection antibodies is > 10 ng/ml of Ig in the
supernatant of each well (Figure 3.2) - a concentration much less than that estimated to result
during microengraving for 2 h with ASCs (1-10 pg/mL) [54]. When the full panel of capture and
detection species was used, apparent cross-reactivity of antibodies and/or bleed through of signal
was corrected for with appropriate compensation to minimize false positives based on results
from spot assays.
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3.2. Optimization of on-chip image-based cytometry for immunophenotyping of human B
cells
The evolution of B cells from plasmablasts to terminally differentiated plasma cells is
accompanied by the increased expression and/or downregulation of CD 19, CD20, CD3 8 and
CD138 cell-surface receptors [55]. A panel of detection antibodies against these receptors was
validated for the analysis of B cells in nanowells by image-based cytometry. Several clones of
antibodies specific for CD19, CD20, CD27, CD38 and CD138 receptors, and conjugated to a set
of fluorophores known to show minimal bleed-through into other channels on the available
epifluorescence microscopes (Zeiss) were tested on PBMCs from healthy donors (Figures 3.3a
and A.1, Appendix). The distributions of populations enumerated on-chip were similar to those
determined by flow cytometry for the same pool of cells, stained at the same time (Figure 3.3).
These results indicate that image-based cytometry can sufficiently resolve the major classes of B
cells, despite the narrower dynamic range typically available on epifluoresence microscopes
equipped with CCDs.
3.3. Optimization of conditions for activation of memory B cells
Antibodies secreted by plasma cells in primary samples can be captured readily with
microengraving. The capture of antibodies from memory B cells, however, requires activation of
this otherwise dormant population. Several stimulation conditions modified from published
conditions for the polyclonal activation of B cells [44-51] were initially compared using a
Luminex* isotyping kit (Millipore). After incubation of PBMCs in media containing stimulants
for 7 days, the isotypes and amounts of antibodies accumulated in the recovered supernatants
was measured (Figure 3.4a). The top three conditions resulting in the most secretion and the
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greatest diversity of antibody isotypes (CpG + IL- 15, CD40L + IL-21 and IL-2 + IL-21 + anti-
human CD40 + anti-human IgM) were subjected to a time course analysis using microengraving.
PBMCs from a single donor were incubated for 3, 5 and 7 days in the different cocktails of
stimulants, after which samples were enriched for B cells, and antibodies secreted by individual
cells were captured by microengraving, using the optimized panel of antibodies for determining
isotype. From this experiment, it was determined that stimulation for 7 days was optimal (Figure
3.4b). After repeating chip-based analysis on multiple PBMC samples stimulated for 7 days, it
was found that stimulation with CD40L + IL-21 was best, inducing secretion from ~20% of
CD20* cells (Figure 3.4c). Naive B cells (CD20*, CD27-, IgM*, IgD*) represent 50-70% of this
population [55, 56], hence, we are able to activate 40-60% of total memory B cells with this
protocol. A 100x dilution of purified Epstein-Barr virus (EBV, Advanced Biotechnologies Inc.)
was included in the mixture to improve the yield of activated cells, and take advantage of
potential synergistic effects from the combination of EBV and polyclonal B cell activators [19,
57, 58]. Although EBV is capable of selective immortalization of human B cells, which may
skew the observed response from the memory B cell population, it was reasoned that the 1 week
timeframe used for activation was too short to significantly alter the repertoire, as
immortalization is typically performed over 2-4 weeks [19, 57-59].
3.4. Optimization of single-cell recovery from nanowells
In order to establish stable cell lines producing antibodies with desired functionalities, it
was imperative that clones of interest could be transferred routinely from wells in an array of
nanowells to larger vessels for clonal expansion or gene amplification. The AVISO CellCelector
automated micromanipulation system (ALS GmbH) was used to rapidly transfer cells from
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nanowells to 96-well microtiter plates. The system comprises a robotic arm carrying a module
for single-cell retrieval (single-cell module, ALS GmbH); an inverted microscope (CKX41,
Olympus) with an imaging CCD (CC12, Soft Imaging Systems GmbH) and an automated
translation stage on which arrays of nanowells were mounted; reservoirs for both media and
sterilizing solution (e.g. 70% v/v ethanol); and docks for mounting 96-well receiving plates. The
single-cell module mounted on the robotic arm includes a glass capillary (50-pm diameter)
connected to a 50 tL syringe via plastic tubing and a series of connectors (Figure 3.5). The hose,
syringe and capillary tip were filled with mineral oil (Sigma), and air bubbles excluded to allow
for precise aspiration of specified volumes. The arm was designed for a repetitive accuracy of at
least 10 pim, and movement of the microscope stage was designed to be accurate to within 1 pim.
Microscope images on this system were acquired at lOx magnification with a camera resolution
of 1.024 pm/pixel. The instrument was operated in both a semi-automated manner, with direct
input of the location of each target nanowell by the user, and in a fully automated mode. A
custom software module (ALS GmbH) was developed to calibrate the system for the
arrangement of the nanowells on a given array, and to import a list of well positions of interest
(encoded by block, row, and column) from the analyzed microarrays generated by the
microengraving process (comma-delimited text file generated from GenePix Pro). Images were
recorded both before and after micromanipulation to validate the retrieval of targeted cell(s).
3.4.1. Optimization of parameters affecting the transfer of viable cells
While the micromanipulator used in these experiments is designed to allow fully
automated recovery of cells, it was useful to operate the instrument in a semi-automated mode to
optimize the system for reliable recovery of single cells. In this mode, cells of interest in
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nanowells were positioned manually for recovery and then retrieved by initiating a programmed
routine for retrieval by the micromanipulator. We used this mode to minimize the time required
to transfer a single cell from a given nanowell to the well of a 96-well microtiter plate, while
maximizing the accuracy of the transfer. Four parameters were considered: (1) the volume of
media aspirated into the glass capillary from a reservoir of media (0.5 ptL, 1.0 pL, 2.0 piL) prior
to retrieving a cell, (2) the volume of media aspirated upon positioning the tip of the capillary
within the targeted nanowell (0.5 pL, 1.0 pL, 2.0 ptL), (3) the time allowed to elapse immediately
after aspiration (0 s, 5 s, 10 s), and (4) the inclusion of a rinse cycle in the destination well of the
microtiter plate immediately after deposition of the retrieved cell (Yes/No).
Liquid uptake for buffer-layer and cell retrieval
We found that pre-aspiration of media was necessary to minimize the likelihood of
trapping the retrieved cell at the interface between the mineral oil in the capillary and the
aspirated media. Pre-aspiration of 0.5 pL of media from the reservoir of media followed by
aspiration of 1.0 pL upon positioning the tip at the nanowell was sufficient to recover single cells
from a targeted well in the array without disturbing cells in adjacent wells (Table 3.1). These
volumes greatly exceed the nominal volume of each nanowell (125 pL), but we did not observe
any non-specific aspiration of cells from adjacent nanowells under these conditions. Volumes
smaller than 1.0 tL, however, were unreliable at removing cells from the targeted wells. The rate
of aspiration was fixed at the lowest setting possible on the instrument (~0.2 pL/s) in an effort to
minimize the possible effects of shear stresses on the retrieved cells. At this rate of aspiration, it
was estimated that the maximum stress on the surface of a cell at any instant would be ~100
dynes/cm 2 , when modeling a cell as a rigid structure in a flow channel. Mammalian cells have
39
been exposed to this shear stress without significantly altering expressed phenotypes or
damaging cellular integrity [60].
The distance set between the glass capillary tip and the surface of the PDMS chip during
the calibration of the instrument also impacted the recovery of viable cells. Positioning the tip
-20 pm from the bottom surface of the nanowells allowed sufficient clearance between the tip
and the surface of the PDMS for aspiration, and avoided direct contact with the cell in a well.
The flexibility of the PDMS substrate was useful for preventing damage to the tip during
calibration, and thus, accurate and reproducible positioning of the tip in nanowells was possible.
Inclusion of rinse cycle in transfer process
To ensure recovered cells were transferred consistently to the receiving plate, it was
critical to rinse the capillary inside the targeted well of the microtiter plate after dispensing the
aspirated volume. Mock transfers were performed immediately after depositing retrieved
HYB099-01 hybridoma cells in the desired destination wells of a microtiter plate, to determine
whether or not all recovered cells had been successfully ejected from the tip. After the initial
transfer of targeted HYB099-Olcells to a well of the 96-well collection plate, the tip was moved
over to an empty nanowell, and the media in the nanowell was aspirated. The aspirated content
was then dispensed and rinsed in media in an unused well of the 96-well collection plate. The
plate of recovered cells was incubated to allow for the expansion of any transferred cells.
Colonies of cells grew only in those targeted wells of the microtiter plate where cells were
intentionally deposited; 17 of the 23 wells in which cells were specifically deposited yielded
expanded populations of cells after incubation. These experiments confirmed that recovered cells
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were transferred to targeted wells with high fidelity; that is, recovered cells were not left in the
capillary to contaminate subsequent wells on the 96-well plate.
System delay following aspiration
Using this optimized set of parameters for retrieving cells from nanowells and depositing
into the wells of a target receiving plate, we studied the effect of adding a short delay between
aspiration of cells from wells, and subsequently moving the capillary to the receiving plate. We
reasoned that the delay would allow the volume in the tip to equilibrate after the aspiration, and
improve the reproducibility of the transfer. We tested the accuracy and subsequent viability
associated with transferring single cells using two different cell lines (12CA5 and HYB099-01
hybridomas) and programmed delays of 0, 5, or 10 s. These values were selected to be similar in
duration to the time required to aspirate 1 pL (5 s). Delays of both 5 s and 10 s yielded better
accuracy of transfer and improved viability of the retrieved cells than no delay (0 s) (Table 3.2).
The variability in accuracy and survival rate also decreased with increased delays. Although the
delay extended the minimum time required per transfer, we concluded that a programmed delay
of 10 s immediately after aspiration was optimal among the conditions tested. The duration for
the entire optimized process for retrieval and transfer of cells from a nanowell to a 96-well plate,
therefore, requires about 67 s, including the time for translation of the microcapillary tip from its
starting position to the various stations. A Student's t-test comparison of the measured accuracies
and survival rates for both the 12CA5 and HYB099-01 cell lines indicated that the observed
differences in these quantities were not statistically significant (p > 0.05). This analysis suggests
that the optimal settings identified could be used successfully for the accurate transfer of other
hybridoma cell lines, with minimal effect on viability. It was also found that the optimized
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parameters determined in these experiments were suitable for the recovery of both primary
lymphocytes (~75% efficiency) and yeast cells [39, 61]. With these settings, ~50-60 transfers
could be made in 1 h in fully automated operation.
3.4.2. Reproducibility of Recovering Discrete Numbers of Cells
An array of wells containing cells can be cultured for several days after microengraving
[36, 52]. We reasoned that delaying the recovery of hybridomas to allow one to two cellular
divisions may improve the yield of clones that successfully expand after transfer to the 96-well
plate. Using the optimized parameters described above, we tested the accuracy of recovering
defined numbers of cells from nanowells (1, 2, 3, or 4) (Figure 3.6). The numbers of recovered
cells in each well of the 96-well receiving plates were counted manually 1 h after transfer. These
experiments demonstrated that the recovery of single cells was highly reproducible (n = 63
transfers). When more than one cell was recovered from a given nanowell, the number of cells
transferred was typically equal to or less than the targeted number. There was, however, greater
variability in these data than that for the transfer of single cells, and the number of cells present
in the receiving plate occasionally exceeded the targeted number. Comparing the measured
accuracies, retrieval of single cells was ~95% accurate, whereas the retrieval of 4 cells was ~50%
accurate. For all of these experiments, the transferred cells expanded successfully in culture
(Figure 3.6b). Together, these data suggest that expanding the number of cells in each nanowell
prior to their recovery is not critical for successful and accurate recovery. The ability to correctly
transfer cells was further demonstrated by alternating between the transfer of 12CA5 and
HYB099-01 cells identified by microengraving for 100 consecutive picks [62].
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3.5. Optimization of protocol for variable gene amplification
To allow for the recovery of genes coding for the heavy and light chain variable regions
of antibodies, cell retrieval was interfaced with RT-PCR steps to amplify genes from mRNA
synthesized within cells. Optimized settings described in Section 3.3 were changed slightly to
accommodate this linkage. Intact cells were deposited into wells of a 96-well PCR plate
containing < 30 tL of 1x First strand buffer and an RNase inhibitor with no pre-aspiration or
rinse steps (Figure A.2, Appendix). These steps were removed to eliminate a potential source of
contamination, to avoid adding extra volume to the subsequent RT reaction, and to avoid lysing
extremely fragile cells after prolonged storage (~6-24 h) at 4'C. Accurate transfer of cells with
this protocol was demonstrated by the alternating transfer of isolated 4D20 cells and the contents
of empty nanowells (data not shown).
The procedure for performing RT-PCR on retrieved cells was modified from the single-
cell RT-PCR protocol published by Wang et al., (2000) [63]. The most significant modification
to the protocol involves the use of Taq polymerase for first round of PCR despite its lower
fidelity, as it is superior at successfully amplifying mRNA with low-copy numbers [53]. With
this protocol, it was possible to amplify genes from > 0.05 pg of purified mRNA (Figure 3.7).
IgA-specific primers from a published protocol by Bradshaw et al. (2007) [64] (IgA-PCRI, 5'-
GCTCAGCGGGAAGACCTT-3'; IgA-PCRII, 5'-GACCTTGGGGCTGGTCGGGGA-3') were
also included in primer pools. Using 4D20 hybridoma cells, for which heavy and light chain
gene sequences were known, it was determined that the expected error rate for nucleotide
addition when amplifying with Taq polymerase then Pfu polymerase was ~5 x 10~5
errors/nucleotide. This error rate was comparable to the error rate observed when using the
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higher fidelity Pfu polymerase for both the first and nested PCRs. Disruption of cellular
membrane integrity was also enhanced by including a freeze-thaw step after recovery; freezing
cells at -800C and thawing at room temperature before running reactions. Overall, the process
allows the transfer and amplification of heavy and light chain genes from single B cells with ~50%
efficiency (30-70% range), with paired sequences recovered ~40% of the time (Figure 3.8). It is
important to note, however, that the amplification efficiency depends largely on the quality and
state of the cells at the time of recovery. We found that the more activated the cells are at the
time of retrieval, the greater the likelihood of amplifying both heavy and light chain genes.
Significant delays in transitioning to the recovery step also reduce the efficiency of amplification.
3.6. Discussion
We have optimized many commonly used bioanalytical processes and processing
conditions to allow their use in conjunction with arrays of nanowells. By integrating these
different analysis tools, it is now possible to obtain information about the immunophenotypes (or
states) of cells, the functionality of secreted antibodies in vivo, and to determine variable gene
usage for interesting cells, all within a primary screen. We are able to profile 10-15 different
parameters with this integrated approach for B cell analysis - comparable with the number of
parameters that can be analyzed by flow cytometry [24, 25] - but there is still significant room
for improvement.
One major advantage of the microengraving approach that has not been utilized
significantly is the ability to analyze secretion from cells repeatedly, with serial microengraving
[35, 65]. This has not been demonstrated for primary human B cells, as the rates of Ig secretion
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from primary cells appeared to be lower in subsequent rounds of analysis, necessitating longer
incubation times during microengraving. With the incorporation of signal amplification
strategies such as the hybridization chain reaction [66], the incubation time required for
microengraving could be truncated, allowing the generation of multiple antibody microarrays
from the same antibody-secreting cells. Alternatively, exploring approaches to covalently link
captured Igs to the capture surface with formaldehyde and/or imidoesters such as dimethyl
adipimidate (DMA) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) [67, 68], may
allow repeated interrogation of microarrays, also increasing the number of analytes or parameters
that can be detected. Additionally, multiplexing will be achieved with improvements in
microscopy and technologies for the analysis of microarrays. A transition to systems with more
lasers and filters should enable the use of more fluorophores simultaneously.
The gene amplification protocol described here is another area for potential improvement.
Currently, the protocol results in the successful amplification of variable genes from -50% of
recovered cells. While this efficiency is comparable with the efficiencies observed with other
approaches [30, 34, 53], the inconsistency observed is concerning. Reasons for this inconsistency
are thought to include problems with primer design and insufficient mRNA in the cells - either
due to mRNA degradation or insufficient activation of cells. Our protocol for single-cell RT-
PCR was designed to be flexible so changes to the primer sets used for gene amplification can be
implemented easily. To increase the amount of mRNA available for heavy and light chain gene
amplification, in vitro transcription methods [69] could also be adapted into the protocol. To
address potential problems with memory B cell activation, transfection of primary memory B
cells with oncogenes [70] could convert these cells into stable antibody-producing cell lines with
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large quantities of mRNA, characteristic of hybridoma cells. Lastly, faster retrieval of cells from
nanowells, either by accelerating the pipeline for analysis of microarrays, or by a redesign of the
micromanipulation system to eliminate extensive translation steps, may minimize any
degradation of mRNA molecules.
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Figure 3.1: Detection of antibody isotypes secreted by human primary B cells.
ASCs were loaded into nanowells and microengraving was performed to capture secreted
antibodies. Representative micrographs of the different isotypes detected are shown, with signals
gated as positive for IgG1, IgA1/2, IgG3, IgM highlighted, after interrogation with optimized
panel of anti-human Ig detection antibodies.
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Figure 3.2: Evaluation of detection limits with optimized panel of secondary antibodies.
Titrations of isotype standards in triplicate were spotted on a uniform donkey anti-human Ig
capture surface. Following incubation of spots, optimized panel of mouse anti-human IgG 1-
Alexa 647, IgA-Alexa 594, IgG3-Alexa 555 and IgM-Alexa 488 detection antibodies, each at 1
pg/mL, was used to evaluate the limits of detection and the amount of signal bleed-through or
antibody cross-reactivity for which to compensate. Each plot shows median fluorescence
intensities (MFI) in the different emission channels used for the different dilutions of a given
isotype standard, spotted on a slide. MFIs from PBS control spots are indicated with red dashed
line.
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Figure 3.3: Comparison of on-chip cytometry and flow cytometry.
PBMCs from a healthy donor were stained for viability with Calcein violet AM, and for
expression of CD 19, CD20, CD3 8 and CD 138. A portion of the labeled cells were loaded onto
an array of nanowells and imaged by epifluoresence microscopy. The remaining cells were
analyzed on a BD LSRFortessal cell analyzer. (a) Representative micrographs from wells with
single cells displaying different expression patterns. Signals gated as positive with custom-built
analysis script are highlighted with orange boxes for each. (b) Density plots of both flow
cytometry (top) and on-chip cytometry (bottom) generated from the same sample.
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Figure 3.4: Optimization of conditions for stimulation of memory B cells ex vivo.
(a) After incubation of PBMCs with mixtures of different cytokines, mitogens and TLR agonists,
supernatants were analyzed for Ig secretion with Luminex kits. (b) The best three conditions
identified in a were subjected to time course analysis using microengraving to determine when to
process stimulated memory cells. (c) Frequencies of activated CD20 cells following 7 days of
bulk stimulation with best conditions for three donors.
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Figure 3.5: Instrument for transferring cells by automated micromanipulation
Photograph of the CellCelector showing the positioning of samples and buffers during the
automated recovery of cells from an array of nanowells. (Inset) Enlarged photograph of the
single-cell module fit with a 50-pim glass capillary that enables the aspiration and transfer of
cells from nanowells.
55
56
Table 3.1: Optimization of liquid uptake for accurate cell retrieval
Accuracy (%)
Pre-aspiration Volume (puL)
0.5 1.0 2.0
Aspiration 0.5 -_85.7 (7)* 37.5 (8)*
Volume 1.0 100.0 (8) 90.0 (10) 50.0 (10)
(pL) 2.0 - 75.0 (12) 42.9 (7)
*Values in parentheses indicate the number of picking events contributing to the calculated
percent accuracy of transfer.
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Table 3.2: Effect of delay on retrieval of 12CA5 and HYB099-01 cell lines
Delay after aspiration 12CA5a HYB099-01a
Os 87.4 3.8 68.1 ±21.0
Accuracy (%) 5 s 85.0 3.8 83.8 ±14.4
lOs 92.1 3.6 78.2 9.2
Os 92.2 5.6 79.8 ±10.1
Survival Rate(%) 5 s 96.9 ±3.6 69.3 ±18.5
10 s 93.6 ± 0.5 79.3 ± 6.8
a Minimum of 52 cells retrieved from independent wells per experiment. Experiments for
each condition replicated three times. Cells only recovered from single-cell wells.
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Figure 3.6: Efficiency of cell transfer with automated micromanipulation system
(a) Assessment of the accuracy of transferring HYB099-01 cells from 50-pm nanowells to 96-
well plates. (b) Box plot of number of cells present after three days of incubation. Box plots
follow Tukey's convention, with the center line representing the median and the upper and lower
edges of the box representing the values of the upper and lower quartiles. Notches on the box
adjacent to the median value represent the p < 0.05 significance interval. Bars extending from
each end of a box represent the most extreme values within 1.5 times the interquartile range.
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Figure 3.7: Establishing limit for amplification of antibody genes with RT-PCR protocol.
Ten-fold serial dilutions of purified mRNA from 4D20 cells were amplified with optimized RT-
PCR protocol. Heavy chain variable genes, 350-400 bp in size, were successfully recovered for >
0.05 pg of mRNA.
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Figure 3.8: RT-PCR amplification of heavy and light chain variable genes from primary B
cells.
Contents from nanowells (n = 24) matching with Ig secretion events on a printed microarray
were recovered from a chip loaded with primary lymphocytes, amplified using optimized RT-
PCR protocol, and resolved on a 1.5% agarose gel. Paired heavy and light chain genes were
amplified in 12 of the reactions (50% efficiency). Unused wells of 96-well PCR plate served as
negative controls and mRNA (~10 ng) extracted from 4D20 cells was used as positive control.
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CHAPTER 4: CHARACTERIZATION OF HIV-INDUCED ANTIBODY RESPONSES
IN MUCOSAL TISSUES
4.1. Background
4.1.1. Impact of HIV/AIDS pandemic
Since the identification of HIV-1 as the causative agent of the acquired
immunodeficiency syndrome (AIDS) in the 1980s, the HIV/AIDS pandemic has been
responsible for millions of deaths worldwide. Following the original outbreak of the disease, the
spread of the epidemic globally was fairly rapid, adversely affecting the health and social well-
being of individuals in different populations, and from various socioeconomic backgrounds.
Current estimates indicate that over 30 million people are infected with HIV-1, and even with the
availability of therapeutic drugs, HIV/AIDS remains a major cause of mortality worldwide, with
increasing prevalence in some communities [71, 72]. Thus far, HIV-1 has stymied clinicians and
scientists, and at present, no cure exists for HIV/AIDS, neither is there a vaccine to prevent
against acquisition of the disease.
4.1.2. Overview of HIV-1 pathogenesis
HIV-1 is a lentivirus that preferentially infects the immune cells of the host, specifically
the CD4* T cells, macrophages and dendritic cells, which are important for mounting an immune
response to any invading pathogen. Virions exist in the blood and reproductive fluids of infected
individuals; hence the virus is transmitted by intermixing of these bodily fluids between infected
and uninfected persons. On entry of the virus, free-floating virus particles fuse with host cells,
injecting viral genetic material into the cell, and then take advantage of cellular machinery for
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viral replication and assembly [72]. Initial infection by HIV- 1 is generally followed by an acute
phase of infection where virus replication is exponential, resulting in a sharp increase in viral
load that manifests with typical viremic symptoms in the patient. At this stage, the immune
system is still able to mount a response, causing a reduction in viral load. The infection, however,
is not eliminated, but progresses into a chronic phase [72]. In the chronic phase, the virus
remains dormant within cells, with periodic replication to maintain the virus reservoir. This stage
is accompanied by a gradual decline in the number of CD4+ T cells and a steady increase in viral
load, until the patient has < 200 CD4* T cells/ml of blood and > 100,000 copies of viral RNA/ml
of plasma, at which point the individual develops AIDS [72]. Such a person is severely
immunocompromised and is highly susceptible to infection by other pathogenic species,
eventually ending in fatality.
4.1.3. Therapeutic strategy for controlling disease progression
Existing treatment for HIV-1 infection involves the use of HAART (highly active
antiretroviral therapy), a cocktail of inhibitory molecules, designed to interfere with the function
of enzymes and structural proteins at different stages in the replication-cycle of the virus.
HAART has been effective in patients, enabling control of the virus in both the acute and chronic
phases of infection. With HAART, there is a reduction in the viral load in infected patients, and
these individuals maintain their CD4+ T cell count at a level sufficient to prevent progression to
AIDS. Despite its utility as a therapeutic option, however, HAART is not the perfect solution in
the global battle against HIV-1. First, HAART is largely ineffective against latent infection, and
thus, unable to confer sterilizing immunity [73]. Though it reduces the risk of transmission, it
does not fully eliminate the possibility of transmitting the virus to others [73, 74]. Moreover, the
success of HAART greatly depends on strict adherence to a lifelong drug regimen that is
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expensive. As a consequence, HAART is widely unavailable to patients in areas where the
transmission rate of the disease is highest. The development of drug resistance in HIV-1
infections is also documented [72]. Therefore, if the disease is to be eradicated, it is necessary to
develop a vaccine as a means of conferring protection against infection by HIV-1; a view
advocated by the scientific community [72, 75-77].
4.1.4. History of HIV/AIDS vaccine development and research
Lessons from past global health crises and pandemics, such as the smallpox and polio
epidemics, indicate that antibody-based vaccines represent a proven strategy for dealing with
viral infectious diseases. Hence, vaccine research over the past three decades has focused
principally on eliciting a humoral response to the virus, particularly neutralizing antibodies that
would eliminate virus particles in the periphery, well before interaction with host cells.
Traditional approaches for priming antibody production with a vaccine, however, have failed to
protect against infection by HIV-1 [76-78]. Progress made in studies of vaccine strategies against
viral surrogates, such as the simian immunodeficiency virus (SIV), in non-human primate
models have also been difficult to replicate against HIV-1 infection in humans [79, 80]. Attempts
at designing vaccines to stimulate effector functions of other immune cells have also been made,
albeit without success [74, 78]. The numerous failed attempts at developing a vaccine or
immunotherapeutic strategy for protection from HIV- 1 infection - especially the recent failure of
the MERCK vaccine [77, 81] - indicate that current knowledge of the interactions between the
host immune system and the virus is inadequate.
Reevaluating the protective capability of antibodies, the characterization of the immune
responses in long-term non-progressors (LTNP) or elite controllers, a cohort of individuals
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capable of maintaining HIV- 1 in a non-pathogenic state without the use of HAART, and highly
exposed, persistently seronegative (HEPS) persons suggest that neutralization by antibodies,
among other mechanisms, could be considered responsible for the regulation of viral
pathogenesis [3, 72, 82, 83]. Analyses of sera from individuals with progressive disease also
suggest that 20-30% of infected persons develop potent neutralizing antibody responses that
unfortunately lag behind evolution of the autologous strain of HIV-1 [84, 85]. In the typical
response to HIV-1, the bulk of antibodies produced recognize decoy epitopes on free-floating
fragments of the Env spike protein. Antibodies binding highly conserved epitopes are infrequent
[84, 86], and hence, have been difficult to isolate. Even with recent successes at recovering
potent neutralizing antibodies [87-93], an effective vaccine strategy remains elusive. One
hypothesis for why, is that there is a limited understanding of the pathophysiology of HIV-1
infection, especially in the mucosa [94-96]. Most knowledge of infection by HIV- 1 comes from
the analysis of blood samples from infected and healthy donors, but mucosal surfaces - through
which infection is typically established - have been poorly characterized. Given the invasive
nature of sample extraction from mucosal tissues, sample sizes are often insufficient for detailed
analyses with existing approaches; hence, responses in these tissues are not fully understood.
With microengraving technology, it is now feasible to perform multiparametric characterization
of immune cells in small tissue samples, allowing the study of the humoral immune response to
HIV- 1 at the primary site of infection and/or in associated lymphoid tissues.
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4.2. Identification of antigen-specific B cells in samples from HIV-infected subjects
4.2.1. Detection of HIV-specific antibodies
One advantage of microengraving is the flexibility to interrogate the resulting antibody
microarrays with different probes to highlight specificities for different antigens. In HIV-1
infection, a major antigen encountered by lymphocytes is the Env spike protein [75, 78, 97, 98].
The gp140 protein (comprising gp120 and gp4l subunits) is highly immunogenic, and there is
evidence from serum analysis that antibodies are raised against several of the epitopes displayed
[84, 89, 90, 98]. To develop an assay suitable for highlighting cells secreting Env-reactive
antibodies in a population, inactivated virus-like microvesicle (MV) preparations displaying
gp160 [99] (HIV-1 BaL strain; courtesy of J. Lifson, Frederick National Laboratory),
recombinant gp140 and gp120 proteins (HIV-1 YU2 strain; IAVI), and peptide mimetics of the
gp41 membrane proximal external region (MPER; 179.4, LLELDKWASLWNWFDITNWLWY
IKKKK-biotin and 57, ELLELDKWASLWNRRK-biotin; courtesy of M. Zwick, Scripps
Institute) were used. Hybridoma cell lines secreting b12 (anti-HIV-1 gp120), 2F5 (anti-HIV-1
gp41) and 4D20 (anti-HA) served as control cell lines. Following the capture of secreted
antibodies, the acquired microarrays were panned with a solution of antigens, then with
secondary reagents to detect bound antigen. The relative affinities of captured antibodies for
different antigens were obtained by comparing the ratios of background-corrected median
intensities from the antigen-specific and Ig-specific channels. With thresholds set such that
statistical specificities were > 95%, statistical sensitivities were calculated to be 2 88 % for all
strategies, especially with HIV-1 BaL MVs and MPER 57, where sensitivities were > 99.9%
(Figure 4.1). Specificity was also maintained when antigens were combined and used
simultaneously (Figure 4. ld).
71
To determine the lower limit of detection for rare cells with microengraving, serial
dilutions of b12-secreting cells were made in a bulk culture of 2F5-secreting cells down to a
frequency of 1 b12 cell in 10,000 2F5 cells. Diluted samples were loaded onto arrays of
nanowells, the original occupancy of each well was recorded with fluorescence microscopy, and
microengraving was used to capture b12 and 2F5 antibodies. The resulting microarrays were
probed with HIV-1 BaL MVs to pin-point locations of the less frequent b12 cells. It was
estimated that rare cells at a frequency of ~0.001 % could be accurately detected (Figure 4.2).
This result suggests that the limit of detection scales directly with the number of wells analyzed
(~10 5 wells/chip), and cells present at lower frequencies could be identified by using multiple
chips.
4.2.2. Analysis of primary B cells from an HIV-infected subject
To demonstrate the utility of this microengraving approach for the characterization of
human primary B cells, PBMCs from an HIV-1 elite controller (CTRO 118; courtesy of D. Kwon,
Ragon Institute) were analyzed, enumerating responses from both plasmablasts/plasma cells and
memory B cell populations. The immunophenotypes of B cells and the overall distribution of
antibody isotypes in each population were determined (Figure 4.3). Microarrays generated were
probed with monomeric HIV-1 YU2 gp140 to identify wells with B cells producing Env-specific
antibodies, and a fraction of antigen-specific cells were recovered with the CellCelector. For this
subject, no Env-specific events were found among actively-secreting cells (ASCs), but -0.5% of
Ig+ events were Env-specific among memory B cells. Heavy and light chain genes were
amplified then sequenced, and with this information, germline gene usage, mutation rates and
complementarity determining region 3 (CDR3) lengths were determined using algorithms
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available on IgBLAST and IMGT databases [100, 101]. Six antibodies (Table A.2, Appendix)
for which paired heavy and light chain sequence data were available were cloned into human
IgG1 and Igi/IgA expression vectors using . co/i, and then expressed transiently as full-length
antibodies in HEK 293T cells. Dilutions of the supernatants containing expressed Ig, and a set of
well-characterized control antibodies, were applied to custom protein microarrays comprising a
cross-clade panel of HIV-1 antigens (Table A.3, Appendix) and an anti-Ig capture antibody (for
normalization of the data) (Figure 4.4). Some of the antibodies exhibited breadth in binding for a
number of gp120 variants across all clades (MIT 44, 45, 64, 65), and another exhibited
preference for gp4l (MIT 78). Due to problems with cloning and expression of some antibodies,
an accurate assessment of the overall false discovery rate could not be made. Nonetheless, these
results demonstrate that microengraving can identify antigen-specific antibodies from human B
cells, and can easily accommodate the comparative analyses of B cells from different cellular
compartments.
4.3. Multiparametric characterization and comparison of ASCs in blood and GALT
Gut-associated lymphoid tissue (GALT) represents the largest reservoir of immune cells
in the body and is a site of constant interaction with commensal bacteria and exogenous
pathogens ingested along with food and drink [1, 95]. In HIV-1 infection, evidence exists that
GALT remains an active reservoir for viral replication, even when virus is undetectable in
circulation [100, 101], but the site has yet to be examined extensively with single-cell resolution
to understand the effects of HIV-1 on the local humoral immune response. The ability to isolate
small numbers of cells using arrays of nanowells makes this process well-suited to characterize B
cells recovered from other anatomical sites such as the colon, small bowel or reproductive tracts.
To study the effects of HIV infection on the humoral response in GALT, ~105-106 ASCs in the
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blood, colon and small bowel (duodenum and terminal ileum) of individuals at different stages of
HIV-1 infection (progressors, controllers and negatives; Table 4.1) were profiled for
immunophenotypes, distributions of secreted isotypes (Figure 4.5 and Table A.4, Appendix),
specificity and relative affinity to HIV-1 BaL MVs (Figures A.3 and A.4, Appendix), and for a
subset of cells, the genes encoding the heavy and light chains on antibodies produced (Table A.5,
Appendix).
Limiting analysis to wells with < 10 viable cells (~1 B cell/well), IgGI was observed to
be the predominant isotype detected from cells in circulation, as expected [1]. Statistical analysis
of the frequencies of the different isotypes examined (IgGI, IgA1/2, IgG3 and IgM), using the
non-parametric Friedman test, also revealed a significant increase in the frequency of IgA
secreting cells in gut tissue, relative to blood (p < 0.0002; Table 4.2), as expected [102]. Changes
in the frequency of cells producing IgA, however, were most dramatic in the colon, upon
progression of disease. The average frequencies of IgA* events enumerated for HIV-1 negative
subjects, controllers and progressors were 64 ± 32%, 58 ± 21% and 29 ± 30%, respectively. A
one-tailed Student's t-test pairwise comparison of the average frequencies (assuming unequal
variances) indicated that IgA production was comparable between negatives and controllers, but
significantly lower when controllers were compared to subjects with progressive disease (p <
0.05). The loss of IgA production is consistent with a previous observation of notable B cell
dysfunction in the colon following infection by HIV [103], and this state appears to persist even
after treatment with HAART. Whether or not this is a direct effect of CD4+ T cell depletion in
the gut is still unclear [94-96].
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Analysis of heavy chain sequences from unique clones (n = 205) identifed as Env-
specific with the Immunoglobulin Analysis Tool (IgAT) [104] using default settings revealed
prevalent use of VH3-23, DH6-19 and JH4 genes (Figure 4.6). The median CDR3 length estimated
was 42 nucleotides (14 amino acids) with a standard deviation of ~10 nucleotides (-3 amino
acids) (Figure 4.7). There was also evidence of antigenic selection during affinity maturation in
18% of the clones (a = 0.05) (Figure 4.8). Comparing V, D and J gene usage for the heavy
chains of Env-specfic clones across compartments, differences were observed only for the
dominant VH gene segments used (Figures A.5, A.6 and A.7, Appendix). In the blood, both VHI-
69 and VH5-51 gene segments were found to be equally prevalent in Env-specific antibodies.
VH3-30 and VH3- 2 3 were the genes present, most frequently, in Env-specific antibodies found in
the colons and small bowels of HIV-infected subjects, respectively. Comparing the distributions
of CDR3 lengths for Env-specific clones across each compartment using a Student's t-test, we
found that the distributions were not significantly different. The median CDR3 lengths were also
similar (blood - 42 nucleotides, colon - 45 nucleotides and small bowel - 42 nucleotides; Figure
A.8, Appendix).
Validation of Env-reactive antibodies focused mostly on class-switched antibodies (non-
IgM), that had long heavy chain CDR3s (> 17 amino acids), were heavily mutated relative to
germline (> 20 nucleotide mismatches) or showed significant binding of HIV-1 BaL MV bait
(backgroud corrected MFI > 2000) in the primary screen (Table A.3, Appendix). Supernatants
from transfection cultures were panned against a cross-clade panel of HIV-1 Env antigens on
custom microarrays, and ~60% showed specificity for at least one antigen in the panel of Env
proteins (Figure 4.9). Two antibodies (MIT 34 and 41) were also found to neutralize a few
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representative tier 1 strains of HIV-1, albeit with less potency than 2G12 - a well-characterized
neutralizing antibody (Figure 4.10; Table A.6, Appendix). Hiearchical clustering of binding
profiles to the set of HIV-1 Env antigens used suggests that other antibodies (e.g. MIT 109 and
135) may have neutralizing activity (Figure 4.9b). Furthermore, there appeared to be a limited
overlap of Env-specific clones across anatomical sites. From a comparison of mutation rates in
the variable genes of recovered antibodies (Figure 4.11), there was a higher mutation rate in gut
tissue, indicative of greater turnover and more activity in these sites. These observations,
however, may be due to a limited sampling of the overall B cell repertoires in these
compartments. To further our knowledge of differences in the B cell repertoires in these sites,
complementary analysis by deep sequencing with next-generation sequencing technology and
lineage analysis of identified neutralizing clones would be informative [105-108].
4.4. Discussion
In our analysis of ASCs in blood and GALT samples, we observed that a reduction in the
percentage of IgA* events in the gut typically follows the transition from controlled infection of
HIV-1 to progressive forms of disease. This reduction is most dramatic in the colon, and is
accompanied by a corresponding increase in the frequency of IgG1* events in this tissue. From
examination of the raw data (Table A.4, Appendix), reductions in the percentages of IgA* events
in the colon appear to be the result of a loss of IgA-secreting plasma cells/plasmablasts in this
anatomical site. IgA-secreting cells are the predominant population of B cells found in gut tissue
[102], and IgA is one of the few Ig isotypes transported across mucosal membranes, enabling the
neutralization of pathogenic species before permanent, irreversible colonization and infection
can be established [109]. Another hypothesized function of IgA in the gut is to facilitate the
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development of immune tolerance to commensal species in the gut microflora, because this
isotype does not induce a significant inflammatory response when bound to antigen [102, 109,
110]. With the loss of IgA secreting cells, the gut becomes a highly inflammatory environment,
suitable for replication of HIV-1 and capable of sustaining a reservoir for the virus. Our results
are, therefore, reasonable, and consistent with previous observations of persistent inflammation
in the guts of patients chronically infected with HIV- 1 [111]. Further analyses to determine the
effects of HIV-infection on humoral responses in GALT should include the examination of
patterns of homing receptor expression on B cells in GALT - specifically CCR9, CCR10 and
a4p7 receptors [102] - for HIV-1 negatives, controllers and progressors, as well as patterns of
expression for exhausted B cell phenotypes [112]. Frequencies of neutralizing antibodies in this
anatomical compartment should also be enumerated with the aid of deep-sequencing
technologies and computational analysis, to discover any HIV-induced changes.
Although the microengraving approach described here measures binding of Env and not
neutralization, binding is a necessary condition for neutralization, and we have found
neutralizing antibodies after cloning and testing only a handful of the Env-specific antibodies
recovered. Both MIT 34 and MIT 41 have heavy chains with long CDR3s (24 amino acids) and
mutations in their VH genes relative to germline - characteristics common to all broad and potent
neutralizing antibodies found to date [87-93]. Despite this similarity, MIT 34 and MIT 41 only
showed efficacy at neutralizing tier 1 strains of HIV- 1, suggesting that additional structural
features are necessary for broad and potent neutralization of virus. Interestingly, some of the
Env-specific antibodies recovered with microengraving possess DH genes (DH3-3) recently
implicated in conferring neutralizing breadth and potency [113], therefore, the validation and
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characterization of these and other Env-reactive clones may reveal other key features required for
broad and potent neutralization of HIV-1 in vivo.
It is worth mentioning that the neutralizing monoclonal antibodies recovered were from
screens with HIV-1 BaL MVs. The two HIV-specific antibodies identified with recombinant
HIV- 1 YU2 gp140 monomers, and tested, were non-neutralizing, despite the breadth and high
apparent affinities observed against the cross-clade panel of HIV-1 antigens used. This result
implies that MVs may present adequate levels of functional Env proteins - which is of concern
with recombinant baits [114] - and may be good baits for the identification of functional HIV-
specific antibodies when no prior characterization of neutralizing potency is available. We
believe that most of the antibodies identified as Ig' MV* in the primary screen, but showing no
specificity for any of the Env antigens used in secondary validation, may be specific for other
membrane associated proteins incorporated during the preparation of these virus-like particles
[99]. The presence of self-reactive and polyreactive antibodies in the gut [115] could also explain
the levels of MV-specific responses identified in gut samples from HIV-negative individuals.
Future iterations of secondary validation should include panels of self-antigens to exclusively
highlight HIV-specific responses. Interrogating with combinations of wild-type and mutant HIV-
1 baits, engineered to highlight conserved epitopes, should also improve the yield of functional
antibodies isolated from HIV- 1-infected patients.
Finally, in this study we have recovered Env-specific and neutralizaing antibodies in
samples from HIV elite controllers. Control of HIV-1 infection is typically associated with
improved T-cell functionality, and analyses of sera from such individuals suggest that humoral
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immunity is not a key component for control [116]. These bulk analyses may, however, have
marginalized functional responses present at low frequencies in these individuals. With the
integrated approach for single B cell analysis presented here, lingering questions about the
contributions of the humoral immune system to the control of HIV-infection may be answered,
by allowing the direct examination of this population of cells.
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Figure 4.1: Statistical assessment of the microengraving assay with different baits.
b12-, 2F5- and 4D20-secreting cell lines were seeded into independent arrays of nanowells for
microengraving, and the secreted antibodies captured on slides were probed for presence of IgG
and reactivity with (a) recombinant monomeric HIV-1 YU2 gp140, (b) gpl60-expressing HIV-1
BaL MVs or (c) MPER peptides (179.4 and 57). Ratios of the median intensities for antigen-
specific to Ig-specific signals (Ag/Ig) for each cell line and antigen are shown as box plots. Red
dashed lines represent the thresholds for evaluating sensitivities of the assay; thresholds were set
such that the false positive rates were no greater than 5% for any modality. (d) Control cell lines
(b12, red; 2F5, unlabeled; 4D20, green) were mixed and analyzed by microengraving. The
resulting microarray was panned simultaneously with a combination of Ms (blue) and MPER
57 (green). Composite micrographs from microscopy and microarray analysis are displayed in
the panel. Scale bar, 50 pm.
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Figure 4.2: Sensitivity of the microengraving approach.
Samples with known concentrations of b12- and 2F5-secreting cells were loaded onto chips and
analyzed by microengraving for binding of HIV-1 BaL MVs. Frequencies of b12 cells in the
samples were calculated as the ratio of the number of Ig*MV* spots with bl2 cells present in the
wells, and the total number of Ig* events.
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Figure 4.3: Integrated analysis of humoral responses from ASCs and memory B cells of an
HIV-infected patient.
Bulk mononuclear cells from the blood were profiled for viability, surface-expressed phenotypes,
isotype distribution and specificity of secreted antibodies for recombinant monomeric HIV-1
YU2 gp140. Values in Venn diagrams represent the total numbers of cells on each array of
nanowells. Distributions in pie-charts include events from wells with < 5 live cells (~1 B
cell/well). Apparent relative affinities are presented compared to median values observed from
binding of b12 from CHO cells to HIV-1 YU2 gp140.
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Figure 4.4: Validation of antibodies identified as HIV-1 Env-specific.
Supernatants from cultures of HEK 293T cells expressing recombinant antibodies from screens
were collected and incubated over custom antigen microarrays, along with dilutions of control
antibodies (gp120-specific: bl2, VRC01, b6, PG9, 2G12, 621K and 479?1; gp41-specific 2F5; and
HA-specific 4D20). Binding to spotted antigens and anti-Ig capture species was detected with a
fluorescently labeled goat anti-human Fcy antibody (1 pg/mL, Jackson Immunoresearch).
Relative affinities (Ag/Ig) of the different antibodies tested are presented as a heatmap.
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Table 4.1: Clinical presentation of HIV-infected study participants
HIV
Classification
ARV
Status
Average
Circulating
Viral Load
(copies/mL)
Average
CD4+ T cell
count (cells/pIl)
Untreated Undetectable
Elite
Controller
Viremic
Controller
Chronic
Untreated Undetectable
Untreated
Treated
2163
U ndetectable
Progressor
Chronic
Progressor
Chronic
Progressor
Treated
Untreated
2542
32120
*Limit of detection for assay used is > 75 copies/mL
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Patient ID Gender
~~4N,
CTR0090 Male EliteController
607
J2ZCTR0865
330183
614225
629356
365685
Male
Male
Male
Male
Male
Male
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457
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Figure 4.5: Comparison of isotype distribution of antibodies from ASCs in blood and
GALT of healthy and HIV-infected patients.
ASCs in samples of PBMCs and disaggregated tissue from the colon and small bowel of HIV- 1
progressors (n = 6), HIV-1 controllers (n = 6) and unifected (n = 4) individuals were processed
and analyzed for secretion of IgG1, IgA, IgG3 and IgM isotypes. Analysis was limited to wells
with < 10 live (Calcein violet AM*) cells. Comparison of responses in GALT suggests that
progressor status is associated with loss of a fraction of IgA-producing population.
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Table 4.2: Unadjusted comparison of isotype distributions across anatomical sites
Comparison IgG1 IgG3 IgA IgM
Overall <0.0001 0.7072 <0.0001 0.0002
Blood vs. Colon <0.0001* N.D. <0.0001* 0.0009*
Blood vs. Bowel 0.0003* N.D. 0.0002* 0.0004*
Colon vs. Bowel 0.0731 N.D. 0.0596 0.1129
*Significant after Bonferroni correction for multiple testing (correction within each Ig Abs)
No need for pairwise comparison when the overall p-value is not significant
N.D. - Not done as overall p-value was not significant
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Figure 4.6: VDJ gene usage in HIV-1 Env-specific clones recovered from blood and GALT
Following the analysis of Env-specific clones with opensource software on IMGT/HighV-quest
database, frequencies of the different human V (a,d), D (b, e) and J (c) genes rearranged into
antigen-specific clones were enumerated.
95
El11'.M..'0
IONJ
96
16%
14%
2 1 %
10%
Z 6%
4%
2%
9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84
CDR-3 length (nt]
Figure 4.7: Distribution of CDR3 lengths for heavy chains of HIV-1 Env-specific antibodies
CDR3 lengths of heavy chain sequences were compared for unique clones recovered from the
blood and GALT of HIV-infected subjects analyzed. Median length was determined to be 42
nucleotides.
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Figure 4.8: Inference of antigen selection in heavy chains of HIV-1 Env-specific clones
The ratio of replacement mutations in CDR-H 1 and CDR-H2 (RCDR) to the total number of
mutations in the V region (My) is plotted against Mv. The light gray shaded area represents the 95%
and the dark gray shaded area represents the 90% confidence limit for the probability of random
mutations. A data point falling outside these confidence limits represents a sequence that has a
high proportion of replacement mutations in the CDR. The probability that such a sequence has
accumulated as many replacement mutations in the CDR by random mutation is p = 0.05. An
allocation above the upper confidence limit was considered indicative of antigenic selection.
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Figure 4.9: Validation of HIV-1 Env-specific antibodies from blood and GALT
(a) Supernatants from cultures of HEK 293T cells expressing antibodies recovered from screens
of ASCs in blood and gut compartments with HIV- 1 BaL MVs were collected and incubated
over custom antigen microarrays, along with dilutions of VRCO 1 (gp 120-specific), 2F5 (gp4 1-
specific) and 4D20 (HA-specific). Binding to spotted antigens and anti-Ig capture species was
detected with a fluorescently labeled goat anti-human Fcy antibody. Relative affinities (Ag/Ig) of
the different antibodies tested are presented as a heatmap. (b) Antigen binding profiles from
microarray analysis were clustered using a pairwise average-linkage and Spearman's rank
correlation. High affinity control antibodies were removed to highlight binding patterns of
cloned antibodies. Five families of clones were identified.
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Figure 4.10: Functional characterization of validated HIV-1 Env-specific antibodies.
Neutralizing activity was tested on a subset of validated antibodies and a known neutralizing
antibody (2G12), against a panel of tier 1 and tier 2 HIV-1 strains.
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Figure 4.11: Comparison of Env-specife responses in blood and GALT based on variable
gene sequences.
Mutation rates in Env-specific antibodies recovered from HIV-infected subjects were evaluated,
relative to germline gene segments, from framework region 1 (FWR1) to the end of framework
region 3 (FWR3). Two-tailed Student's t-tests were used for pairwise comaparisons of mutation
rates across the different sites. Statistical significance is indicated with (*) for p > 0.05, (**) for
p > 0.01, (***) for p > 0.001 and (****) for p > 0.0001.
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CHAPTER 5: ISOLATION OF CIRCULATING WNV-SPECIFIC B CELLS WITH
MICROENGRAVING
5.1. Background
5.1.1. Overview of WNVpathogenesis
WNV is a single-stranded RNA virus in the family Flaviviridae, genus Flavivirus along
with viruses such as the Yellow fever and Dengue virus. Originally identified in Uganda in the
late 1930s, the virus has since spread to areas of Europe, Asia, Australia, The Middle East, North,
Central and South America, reaching endemic status in some of these regions in the 2000's [117].
The virus is fairly promiscuous as it infects primarily birds, but also infects amphibians, reptiles
and mammals, including humans [117]. Transmission to humans is predominantly through
mosquitoes of the Culex species, after ingestion of a blood meal from an infected source. Other
modes of transmission include through blood transfusion, organ transplantation and breast milk
[118]. Symptoms of WNV infection are typically observable after 2-14 days, and range from
mild flu-like symptoms to neurological disease in the form of meningitis, encephalitis or acute
flaccid paralysis, and in the most severe cases, death [118]. Fortunately, however, most cases of
infection are asymptomatic. The highest risk of symptomatic infection is found among elderly
and immunocompromised individuals [119].
Positive sense RNA, ~11,000 bp in size, encased in an icosahedral arrangement of capsid
protein is transmitted by a WNV virion. The viral genome codes for structural proteins (capsid,
C; premembrane, prM; and envelope, E) and nonstructural proteins (NS1, NS2A, NS2B, NS3,
NS4A, NS4B and NS5) which are required for replication and immune evasion [120]. The capsid
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is entirely coated with prM, membrane (M) and E glycoproteins, which are responsible for viral
diversity and tropism. As with HIV-1, the envelope protein facilitates entry of the virus into host
cells. The exact populations of cells infected by WNV have not been fully established, but
targets appear to include dendritic cells, macrophages, neutrophils, and neural cells [120-124].
The cell surface receptors required for viral entry are also unknown, but some C-type lectins and
integrins have been implicated in mediating infection in in vitro studies [125-127]. Entry of
VNV into host cells is by receptor-mediated endocytosis. Within the acidic environment of an
endosome, conformational changes in the envelope protein result in the fusion of virions with the
endosomal membrane, allowing injection of RNA into the cells. It is hypothesized that there are
three stages of WNV pathogenesis: infection, amplification and neuroinvasion [120]. Following
infection and spread of the virus, replication occurs in peripheral lymphoid tissues [119]. The
exact mechanism of neuroinvasion is still unknown, but entry into the central nervous system
allows infection of neural cells, causing neurological disease. With treatment or a vaccine, it
should be possible to limit the spread and effects of WNV infection.
5.1.2. Treatment and control of WNV infection
At present, neither a cure nor treatment for VNV infection exists. Cases of symptomatic
disease are typically managed with supportive care. Strategies to stem the spread of infection
have focused on increasing public awareness and education, and control of mosquito vectors.
Studies of the immune system following infection in humans and non-human disease models of
WNNV infection have revealed innate and adaptive (both cellular and humoral) immune responses
that could potentially limit and/or eliminate viral replication in vivo [120, 124, 128]. Of these,
the antibody response is of particular interest, given the significance of neutralizing antibodies in
conferring immunity to viral pathogens. Immunization of mice and rabbits with recombinant
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forms of the E protein has given rise to protective anti-WNV antibodies in these animals [129-
131]. Passive immunization with antisera has also been shown to be effective at protecting
against more severe manifestations of disease in animal models of infection [118, 129, 131, 132].
The E, prM and M proteins of WNV are immunogenic, with a majority of the humoral
response targeting the E protein [129-131]. WNV E protein exists as a homodimer on mature
viral particles [133]. There are three domains (D) of WNV E: DI, DII and DIII. Highly
conserved epitopes - conserved even among other flavivirus species - are found in DI and DII,
along with the fusion loop, required for fusion of the viral and cell membranes [133, 134].
Conserved residues are thought to remain hidden until fusion is initiated in endosomes. DIII of
WNV E is relatively accessible and is involved in receptor binding that precedes endocytosis.
Most WNV-specific neutralizing antibodies that have been discovered from mice and humans
recognize epitopes in this domain [132, 135, 136]. The human monoclonal anti-WNV E
neutralizing antibodies discovered in these studies were identified from combinatorial libraries of
variable genes from convalescent individuals using phage display, raising questions about
whether or not such antibodies could be generated naturally during infection. In this study,
microengraving technology was used to identify WNV E-specific antibodies and to guide lineage
analysis in studying the evolution of the humoral response to WNV infection.
5.2. Discovery of WNV-specific antibodies in samples from infected patients
In preliminary experiments, it was determined with polyclonal sera that direct
conjugation of a recombinant, soluble, monomeric WNV E protein [131] (courtesy of R.
Montgomery) to fluorophores (Alexa Fluor* dyes) blocked epitopes required for binding.
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Compatible secondary antibodies for detection of bound E were also not found, hence, solution-
phase presentation of antigen to captured antibodies was not ideal. Instead, poly-L-lysine slides
were coated directly with E protein (50 tg/mL) diluted in borate buffer (pH 9), to mimic the
direct format of an ELISA (Figure 5.1). In theory, with this approach, signal for the presence of
Ig will only be detected in locations mapping to antigen-specific cells, but non-specific
adsorption to protein on slides is also of concern. The false discovery rate due to non-specific
adsorption was estimated to be 0.0048% of B cells (CD19+/CD20* cells) analyzed, based on the
analysis of 4D20 cells (Figure 5.2). Registration of elements on microarrays was facilitated by
concurrent microcontact printing [137] of fluorescently-labeled BSA used in blocking the surface
of each array of nanowells.
Samples of PBMCs from convalescent and asymptomatic individuals, > 2 years post-
infection, were obtained from an area where epidemic levels of disease had been experienced
(Table 5.1). The presence of a WNV E-specific humoral response was first determined for each
sample by immunoblot analysis of recovered patient sera [138]. Titers of neutralizing antibodies
in serum were also quantified with a quantitative plaque reduction neutralization test (PRNT) to
document that the humoral immune response in these patients was functional [138]. Plasma cell
and memory B cell populations were screened for WNV E specificity in each sample, and cells
producing functional antibodies were recovered for genetic analysis (Figure 5.2; Table A.7,
Appendix). IgAT analysis of somatic hypermutations in heavy chains of E-specific clones
estimated that 6.25% of unique clones recovered were selected for in the presence of antigen
(Figure 5.3). Sequences from amplified genes were made available to collaborators in Kleinstein
lab (Yale Medical School) to assist with lineage analysis, which may help identify families of
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functionally related clones. Antibodies for which there were paired heavy and light chain
variable genes were cloned and expressed in HEK293T cells (Table A.8, Appendix). Expressed
monoclonal antibodies were validated for binding of WNV E on custom protein microarrays. 8
out of 11 successfully expressed antibodies showed some specificity for WNV E in this
secondary validation assay (MIT 87, 89, 90, 91, 92, 93, 94, and 95) (Figure 5.4). These
monoclonals were sent to the Montgomery lab (Yale Medical School) to evaluate their abilities to
neutralize WNV.
5.3. Discussion
Consistent with our expectations, WNV E-specific responses were effectively absent
from the circulating B cell repertoire, except in the sample from one individual. Since PBMCs
were recovered from convalescent patients > 2 years post-infection, and infection by WNV does
not result in chronic disease, all antigen-specific plasma cells or plasmablast in circulation should
have disappeared. Among memory B cells, the average frequency of antigen-specific memory B
cells in the samples analyzed was -0.1% of CD19+/CD20* cells. Comparing the enumerated
frequencies of E-specific antibodies in the memory B cell compartment for each patient, and the
measured titers of neutralizing antibodies in their serum, we find that both variables are
correlated for this limited data set (r = 0.926, p = 0.037; Pearson's correlation, one-tailed test).
Interestingly, the patient with the highest titer of neutralizing antibodies and frequency of
antigen-specific memory B cells was asymptomatic. It is known, however, that the presence and
potency of a WNV-specific humoral immune response is uncorrelated with the severity of
disease (unpublished results, Montgomery lab), hence, further attempts at finding B cells
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secreting potent neutralizing antibodies for the development of vaccines must still include the
analysis of samples from individuals with severe manifestations of infection by WNV.
Along with the enumeration of WNV-specific cells in different B cell repertoires, a
parallel objective for this study was to facilitate the development of a pipeline for genome-wide
analysis of antigen-specific B cell repertoires in infected patients. Given that < 5% of clones in
the memory B cell repertoire show any significant expansion (i.e. > 0.4% of the repertoire) [56],
and considering that ~10 4 -105 useful reads are typically generated with current next-generation
sequencing techniques, lineage mapping for the purpose of comprehensive repertoire analysis
and the identification of functionally-related antibodies could be challenging for the set of
samples collected in this pilot study. For convalescent individuals > 2 years post-infection, it is
likely that the frequencies of unique WNV E-specific clones in the memory B cell repertoire are
< 0.1%. It is, therefore, recommended that future studies of this sort focus on the analysis of
immune responses during acute stages of infections, when WNV E-specific responses would be
dominant.
Overall, we have successfully demonstrated that the microengraving approach can be
readily adapted for the identification of WNV E-specific antibodies. Importantly, the lessons
learned from this course of investigation should inform any endeavors targeted at the discovery
of novel antibodies generated naturally against WNV and other Flaviviridae, such as Yellow
fever and Dengue.
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Figure 5.1: Schematic of direct format of microengraving
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Table 5.1: Clinical presentation of WNV study subjects
U19_ID Recruitment Diagnosis t WNV E IgG NeutralzingSource immunoblot tier*titer*
100041 Texas WNF ++ 1:40
110038 Texas WNF ++++ 1:40
100032 Texas WNM ++++ 1:80
100038 Texas Asymp ++++ 1:160
tWNF - febrile illness, WNM - meningitis, Asymp - asymptomatic infection
* Highest dilution for which 100% neutralization was observed in PRNT
115
116
b
4. 40- M AI
s 35.I A
30-I m Memory B cells2SE
_ 
2"D
C14. . I
N
100041 110038 100032 100038
300-
50 ASCs
250 m Memory
422 0 0 1
20 14
Sample No.
B cels
038 100032 100038
Sample No.
Figure 5.2: Frequencies of enumerated WNV-specific antibodies in circulation.
ASCs and activated memory cells were screened by microengraving to identify naturally selected
E-specific antibodies. The data above represents the frequency of Ag* events (detected as bound
Ig on microarrays with anti-human K and X secondary antibodies, each at 1 pg/mL) from wells
with cells, normalized by the total number of (a) live (Calcein Violet AM*) cells or (b) live B
cells (Calcein Violet AM+, CD 1 9*/CD20*) screened. Additional criteria (CV < 70 and
background corrected MFI > 1500) were included in analysis of microarrays with GenePix* 6.0
to reduce the number of false positives identified. Error bar represents standard error of
measurement from triplicate experiments.
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Figure 5.3: Inference of antigen selection in heavy chains of WNV E-specific clones
The ratio of replacement mutations in CDR-H 1 and CDR-H2 (RCDR) to the total number of
mutations in the V region (My) is plotted against Mv. The light gray shaded area represents the 95%
and the dark gray shaded area represents the 90% confidence limit for the probability of random
mutations. A data point falling outside these confidence limits represents a sequence that has a
high proportion of replacement mutations in the CDR. The probability that such a sequence has
accumulated as many replacement mutations in the CDR by random mutation is p = 0.05. An
allocation above the upper confidence limit was considered indicative of antigenic selection.
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Figure 5.4: Validation of WNV E-specific monoclonal antibodies.
Microarrays with four replicate spots of anti-human Ig (H+L) (300 ng/mL), WNV E (100 Rg/mL)
and IAVI Al (100 pg/mL; negative control) were used to test for WNV E specificity. Dilutions of
supernatant from transfections were incubated over microarrays, and binding was detected with
labeled anti-human Fcy, ic and X antibodies. The concentration of bound Ig in each dilution was
estimated from a standard curve generated with titrations of a control human monoclonal
antibody. Filled markers are for binding to WNV E. Open markers are from binding to IAVI Al.
121
MI
U
MIT8
120
100
T 87
IT 90
A
S125
M 4W0
21W
I S MIT 91
a
MIT 92
530
3,W
230
120
o + *
0.]
600
1o
A
4M0
100
I
I
II
MIT 94
- {)
0 221
Conc~trsUoo (rlglnL)
3lS
122
CHAPTER 6: CONCLUSIONS
Presented in this dissertation is an integrated process for generating detailed profiles of
human humoral responses that highlight characteristics of both antigen-specific B cells and their
antibodies. The approach extends the capabilities of the nanowell platform beyond the
characterization of mouse B cells and hybridomas [35, 36], and incorporates the ability to
recover the genes encoding human antibodies of interest by single-cell RT-PCR. The
combination of on-chip cytometry, microengraving, and RT-PCR yields comprehensive data on
the immunophenotypes of B cells, the isotypes and relative affinities of their antibodies for
particular antigens, as well as the genes of the variable regions of the antibodies. It was shown
that this approach produced detailed profiles of the diversity of HIV Env-specific B cells present
in blood and mucosal tissue, and yielded new antibodies with neutralizing activity. The
technique is also adaptable and was easily modified to enable the recovery of circulating B cells
producing WNV E-specific antibodies in convalescent patient samples.
The integrated process for profiling the breadth of antigen-specific human B cells has
three advantages over methods relying on FACS and other microtechnologies. First, the method
is well-suited to characterize primary B cells from any anatomical site from which a biopsy can
be obtained. The examples shown here with cells from intestinal biopsies underscores the ability
to isolate and interrogate single cells from samples when the total numbers of cells are limited
(~105 cells). This capability should enable detailed profiling of the cells contributing to humoral
responses at sites of infection such as the reproductive tract and other lymphoid tissues. Second,
compared to flow cytometry, microengraving has better sensitivity for rare cells (1-2 orders of
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magnitude) and allows characterization of the specificity of antibodies from plasmablasts/plasma
cells without compulsory recombinant expression. The larger surface area available for the
presentation of antibodies in microengraving, also suggests that there is greater opportunity for
high avidity interactions with antigen, hence, both low and high affinity antibodies are easier to
detect. Third, compared to other microtechnologies demonstrated for antibody screening [33, 34],
the ability to separate secreted antibodies physically from the cells producing them allows for
easy multiplexed characterization and repeated analysis of the antibodies without potential
damage or loss of source cells. Here it was shown that antibody microarrays produced by
microengraving can be probed by inactivated virions, but other modalities of screening that use
intact pathogens (e.g., fungi or bacteria) are also possible (unpublished results, J. Christopher
Love), highlighting the applicability of the method for identifying antibodies of interest in other
disease models.
In spite of the many advantages of the integrated approach for B cell analysis presented,
there are still areas for further technical development. The prolonged period of time between the
analysis of acquired microarrays and the recovery of cells of interest often results in the
degradation or loss of mRNA coding for antibody genes. This delay is hypothesized as one of the
reasons for the reduced amplification efficiency in certain samples. Bead-based approaches for
capturing nucleic acids from cells in micron-scale confinements [139, 140] represent potential
solutions to the problem, if such methods can be implemented immediately after microengraving.
Additionally, the incorporation of technologies with faster rates of single-cell recovery from
arrays of nanowells [141] could enable deeper analysis of antigen-specific B cell repertoires.
Along with improvements in mechanistic aspects of the process, expanding on the technique to
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allow the assessment of other effector functions of antibodies such as ADCC would be valuable
in determining the efficacy of an immune response.
In summary, the microengraving-based approach described in this thesis provides an
efficient and flexible means of assessing global and localized humoral responses to immunogenic
species - which is currently a challenge with existing technology - and also provides a consistent
basis for the analysis and comparison of different B cell subsets. The use of this technique for
the integrated analysis of ASCs and memory B cells from primary human clinical samples should
facilitate the discovery of cells producing antigen-reactive antibodies against targets such as
HIV-1, WNV, autoantigens in autoimmune responses [5, 142] or immunogens used in
vaccination. The routine application of this technology in the analysis of tissue and blood
samples would provide, at the single-cell level, a snapshot of the antigen-specific humoral
response elicited following infection or vaccination. Finally, combined with data from repertoire
analysis by deep sequencing, important connections between function and prevalence of
monoclonal antibodies would help further our understanding of B cell immunology in diseases
like HIV/AIDS, informing the design of therapeutic and/or vaccine strategies against such
elusive targets.
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APPENDIX
Table A.1: Primers for amplification and cloning of heavy and light chain variable genes
Primer Name 5'-3' Sequence Direction Chain Use
VHL-1 TCACCATGGACTGSACCTGGA Forward Heavy PCR I
VHL-2 CCATGGACACACTTTGYTCCAC Forward Heavy PCR I
VHL-3 TCACCATGGAGTTTGGGCTGAGC Forward Heavy PCR I
VHL-4 AGAACATGAAACAYCTGTGGTTCTT Forward Heavy PCR I
VHL-5 ATGGGGTCAACCGCCATCCT Forward Heavy PCR I
VHL-6 ACAATGTCTGTCTCCTTCCTCAT Forward Heavy PCR I
VkappaL-1 GCTCAGCTCCTGGGGCTCCTG Forward Light PCR I
VkappaL-2 CTGGGGCTGCTAATGCTCTGG Forward Light PCR I
VkappaL-3 TTCCTCCTGCTACTCTGGCTC Forward Light PCR I
VkappaL-4 CAGACCCAGGTCTTCATTTCT Forward Light PCR I
VlambdaL-1 CCTCTCCTCCTCACCCTCCT Forward Light PCR I
VlambdaL-2 CTCCTCACTCAGGGCACA Forward Light PCR I
VlambdaL-3 ATGGCCTGGAYCSCTCTCC Forward Light PCR I
C-mu II CAGGAGACGAGGGGGAAAAG Reverse Heavy PCR I
C-gammall GCCAGGGGGAAGACSGATG Reverse Heavy PCR I
IgA-PCRI GCTCAGCGGGAAGACCTT Reverse Heavy PCR I
C-kappall TTTCAACTGCTCATCAGATGGCGG Reverse Light PCR I
C-lambdall AGCTCCTCAGAGGAGGGYGG Reverse Light PCR I
VH-1 CAGGTSCAGCTGGTRCAGTC Forward Heavy PCR II, Sequencing
VH-2 CAGRTCACCTTGAAGGAGTC Forward Heavy PCR II, Sequencing
VH-3 SAGGTGCAGCTGGTGGAGTC Forward Heavy PCR II, Sequencing
VH-4 CAGGTGCAGCTGCAGGAGTC Forward Heavy PCR II, Sequencing
VH-5 GARGTGCAGCTGGTGCAGTC Forward Heavy PCR II, Sequencing
VH-6 CAGGTACAGCTGCAGCAGTC Forward Heavy PCR II, Sequencing
Vkappa-1 CGMCATCCRGWTGACCCAGT Forward Light PCR II, Sequencing
Vkappa-2 CGATRTTGTGATGACYCAG Forward Light PCR II, Sequencing
Vkappa-3 CGAAATWGTGWTGACRCAGTCT Forward Light PCR II, Sequencing
Vkappa-4 CGACATCGTGATGACCCAGT Forward Light PCR II, Sequencing
Vlambda-1 CCAGTCTGTGCTGACTCAGC Forward Light PCR II, Sequencing
Vlambda-2 CCAGTCTGCCCTGACTCAGC Forward Light PCR II, Sequencing
Vlambda-3 CTCCTATGAGCTGACWCAGC Forward Light PCR II, Sequencing
C-mu III GAAAAGGGTTGGGGCGGATGC Reverse Heavy PCR II, Sequencing
C-gammallI GACSGATGGGCCCTTGGTGGA Reverse Heavy PCR 11, Sequencing
IgA-PCRII GACCTTGGGGCTGGTCGGGGA Reverse Heavy PCR II, Sequencing
C-kappaIII AAGATGAAGACAGATGGTGC Reverse Light PCR II, Sequencing
C-lambdalll GGGAACAGAGTGACCG Reverse Light PCR II, Sequencing
5' Agel VHI CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG Forward Heavy Cloning
5' Agel VHl/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG Forward Heavy Cloning
5' Agel VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG Forward Heavy Cloning
5' Agel VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG Forward Heavy Cloning
5' Agel VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG Forward Heavy Cloning
5' Agel VH 4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG Forward Heavy Cloning
5' Agel VH 1-18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG Forward Heavy Cloning
5' Agel VH 1-24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG Forward Heavy Cloning
5' Agel VH3-33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG Forward Heavy Cloning
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5' Agel VH 3-9 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG Forward Heavy Cloning
5' Age! VH4-39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG Forward Heavy Cloning
5' Agel VH 6-1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG Forward Heavy Cloning
5' Agel VK 1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC Forward Kappa Cloning
5' Agel Vi 1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT Forward Kappa Cloning
5' Agel VKI 1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC Forward Kappa Cloning
5' Agel Vic 2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC Forward Kappa Cloning
5' Agel Vic 2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC Forward Kappa Cloning
5' Age! Vic 2-30 CTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC Forward Kappa Cloning
5' Age Vic 3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC Forward Kappa Cloning
5'Age Vic 3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC Forward Kappa Cloning
5' Age Vi 3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT Forward Kappa Cloning
5' Age Vic 4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC Forward Kappa Cloning
5' Agel VX 1 CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG Forward Lambda Cloning
5' Agel VX 2 CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG Forward Lambda Cloning
5' Agel VX 3 CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG Forward Lambda Cloning
5' Agel VX 4/5 CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA Forward Lambda Cloning
5' Agel VX 6 CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG Forward Lambda Cloning
3' Sall JH 1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG Reverse Heavy Cloning
3' Sall JH 3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG Reverse Heavy Cloning
3' Sall JH 6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG Reverse Heavy Cloning
3' BsiWI JK 1-4 GCCACCGTACGTTTGATYTCCACCTTGGTC Reverse Kappa Cloning
3' BsiWl JK 2 GCCACCGTACGTTTGATCTCCAGCTTGGTC Reverse Kappa Cloning
3' BsiWI JK 3 GCCACCGTACGTTTGATATCCACTTTGGTC Reverse Kappa Cloning
3' BsiWl JK 5 GCCACCGTACGTTTAATCTCCAGTCGTGTC Reverse Kappa Cloning
3' Xhol Ck CTCCTCACTCGAGGGYGGGAACAGAGTG Reverse Lambda Cloning
3lgVs-PCR-fwd CACTTTGCCTTTCTCTCCACAGGT Forward All Colony PCR
3IgVs-PCR-rev ACAGATGGTTCTTTCCGCCTCAGA Reverse All Colony PCR
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Figure A.1: Validation of anti-CD27 antibody in cytometry panel.
PBMCs from a healthy donor were stained for viability with Calcein violet AM, and for
expression of CD27 only. Labeled cells were loaded onto an array of nanowells and imaged by
epifluoresence microscopy in all fluorescent channels typically used for human B cell
immunophenotyping. Density plots of the signal recorded in each channel after gating for viable
cells are shown.
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Figure A.2: Effect of buffer volume on variable gene amplification efficiency
CD 19+ B cells (n = 30) sorted into 10 ptL of 1 x First strand buffer were obtained courtesy of Dr.
Elizabeth Bradshaw, BWH. To 10 wells an additional 10 pL of 1 x First strand buffer was added,
and to another 10 wells, 20 ptL of 1 x First strand buffer was added before running RT-PCR
protocol. Comparable amplification efficiency was observed even when using larger volumes of
buffer for RT reaction.
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Clone No. Patient Tissue V Region D Region J Region Mutation CDR3 V Region J Region R at n CDR3
MIT 001 013646A COLP IGHV4-304*01 IGHD5-24*01 IGHJ5*02 4.1 CARDLADSYNRLDPW IGKVID-33*01 IGKJ3*01 0.6 CQQYDNLPRGFTF
MIT 020 CTR0865 COLP IGHV1-46*01 IGHD2-15*01 IGHJ6*02 7.2 CARDWPIVVVTTNGYYHGLDVW IGKVlD-39*01 IGKJ3*01 6.7 CQQTYSPPRTF
MIT 029 CTR0090 BLDP IGHVl-69*09 IGHDS-24*01 IGHJ4*02 6.3 CTTDDEPSGHW IGKV2D-28*01 IGKJ4*01 1.5 CMQALQTPLTF
MNT034 013646A COLP IGHVl-69*01 IGHD2-15*01 IGHJ6*02 3.6 CAGQDIVVVMATDADFYYYGLDDW IGLV2-14*01 IGLJ3*02 2.7 CSSHASGDTLVF
MIT 041 013646A COLP IGHV1-24*01 IGHD3-22*01 IGHJ5*02 7.1 CTTTRGQKDYYDGSGVPGIYFDPW IGKVID-12*02 IGKJ4*01 5.0 CQQANSLLALSF
MIT 104 604772 BLDP IGHV3-7*01 IGHD6-6*01 IGHJ2*01 0.0 CARDSSSDGYFDLW IGKV3-1l*01 IGKJ3*01 0.0 CQQRSNWPPT
MIT 106 604772 COLP IGHV6-1*01 IGHD5-24*01 IGHJ5*02 5.7 CARDKTAIGAGYFDSW IGKV1-5*03 IGKJ2*01 5.1 CQHYNSYPYTF
MIT 107 604772 COLP IGHV1-18*01 IGHD6-13*01 IGHJ4*02 6.7 CVRFNRAADYW IGKV3-ll*01 IGKJ4*01 2.1 CQHRYNWPPVTF
MIT 116 931995 BLDP IGHV5-51 *03 IGHD6-19*01 IGHJ3*02 0.0 CARQRQWLAEGAFDIW IGKVID-39*01 IGKJ4*01 3.6 CQQSSRTPITF
MIT 119 CTR0090 BLDP IGHV1-69*09 IGHD5-24*01 IGHJ4*02 7.1 CTTDDEPSGHW IGKV3-20*01 IGKJ2*01 6.8 CQQYGDSPYTF
WMIT 132 629356 BLDP IGHV1-69*12 IGHD6-6*01 IGHJ4*02 3.9 CARDPGVYGEVGLVVGADYW IGKV4-l*01 1GKJ1*01 0.8 CHQYYTTPHWTF
MIT 133 CR0555w COLP IGHV3-33*05 IGHD3-22*01 IGHJ3*02 6.8 CARDFPLSRIPNPYDAIDLW IGKVID-39*01 IGKJ4*01 3.1 CQQSSRTPITF
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Refers to mismatches in FWR1, CDR1, FWR2, CDR2 and FWR3
Antibodies highlighted in green were antigen specific and those in yellow were neutralizing.
Antibody highlighted in grey was identified as negative in microengraving assay.
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Table A.3: Cross-clade panel of recombinant HIV-1 proteins spotted on antigen microarrays
Strain Protein Clade Source
IAVI Al gpl20 A IAVI
YU2 gp120 and gp140* B IAVI
YU2 D368R gpl20 B IAVI
JRCSF gpl20 B IAVI
JRCSF D368R gpl20 B IAVI
JRFL gpl20 B IAVI
JRFL N332A gp120 B IAVI
BaL gpl20 B NIH AIDS Research and Reagent Program
CM gpl20 and gpl40 E NIH AIDS Research and Reagent Program
93TH973 gp120 E NIH AIDS Research and Reagent Program
CN54 gpl20 C/B' NIH AIDS Research and Reagent Program
IIIB gpl20 B NIH AIDS Research and Reagent Program
96ZM651 gp120 C NIH AIDS Research and Reagent Program
UG37 gpl40 A NIH AIDS Research and Reagent Program
UG21 gpl40 D NIH AIDS Research and Reagent Program
SF162 gp140 B NIH AIDS Research and Reagent Program
HxB2 gp4l B Vybion Inc.
MPER 179.4 oligopeptide - Scripps Institute
MPER 57 oligopeptide - Scripps Institute
* Protein exists as a trimeric construct.
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Table A.4: Enumerated frequencies of Ig* events in blood and GALT samples
Secreted Ig
Patient ID HIV Status Tissue Site IgGI IgA IgG3 IgM Total
Blood 2147 7 146 0 2300
013646A Elite controller Colon 2025 755 450 217 3447
Small Bowel 1070 179 31 157 1437
Blood 811 8 5 0 824
CTR0090 Elite controller Colon 2037 6104 6 85 8232
Small Bowel 2122 546 6 154 2828
Blood 2373 35 2 11 2421
CR0555W Chronic progressor Colon 3756 852 3 100 4711
Small Bowel 1918 325 1 138 2382
Blood 2659 29 2 3 2693
CTR0865 Elite controller Colon 3414 3978 11 95 7498
Small Bowel 2414 390 2 156 2962
Blood 1341 83 5 0 1429
CTR0147 Elite controller Colon 2745 5902 5 141 8793
Small Bowel 1475 766 1 136 2378
Blood 883 55 5 0 943
330183 Viremic controller Colon 3313 4400 456 294 8463
Small Bowel 1844 2799 147 194 4984
Blood 2041 38 5 0 2084
629356 Chronic progressor Colon 1695 32 1 0 1728
Small Bowel 1709 37 0 0 1746
Blood 2521 23 0 0 2544
614225 Chronic progressor Colon 1656 83 16 3 1758
Small Bowel 1136 0 9 3 1148
Blood 4595 89 15 4 4703
604772 Chronic progressor Colon 2648 4925 79 45 7697
Small Bowel 945 601 14 45 1605
Blood 4054 15 66 16 4151
931995 Progressing controller Colon 1789 352 26 131 2298
Small Bowel 2725 290 6 169 3190
Blood 5335 21 9 0 5365
966971 Uninfected donor Colon 1850 369 3 30 2252
Small Bowel 1496 188 2 51 1737
Blood 7746 67 3 21 7837
900158 Uninfected donor Colon 1745 9596 16 178 11535
Small Bowel 5957 1820 6 119 7902
Blood 330 5 4 2 341
874612 Uninfected donor Colon 3757 8430 5 45 12237
Small Bowel 2218 7560 2 164 9944
Blood 3989 201 87 28 4305
473516 Elite controller Colon 428 1806 7 5 2246
Small Bowel 4307 843 117 4 5271
Blood 6709 69 26 1 6805
205120 Uninfected donor Colon 687 4129 5 1 4822
Small Bowel 1896 2138 16 58 4108
Blood 575 41 34 30 680
365685 Chronic progressor Colon 1060 2395 10 35 3500
Small Bowel 2009 2884 36 238 5167
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Figure A.3: Relative affinity measurements of IgGI and IgA events enumerated in screens
of blood and GALT samples.
Ratios of background corrected MFIs for captured Ig and bound antigen (Ag) in Ig*MV*
positions were used to calculate relative affinities (Ag/Ig) of HIV- 1 BaL MV reactive spots
identified in the analysis of blood (o), colon (A) and small bowel (0) samples from HIV-1
negatives, controllers and progressors (in order).
149
4'
12-
&£
A
I& 4
4.
aa a
a a
09
~ET
a
150
Isotype: IgG3
8-1 2.5-
*
6-
10.
4;4
FEI
Ueaie oiotr rge~~
2.0-
a
a
Isotype: 1gM
I a
+
=
*a
4-
* AA
a.....c"tfm WP"O
o Blood a Colon o Small bowel
Figure A.4: Relative affinity measurements of IgG3 and IgM events enumerated in screens
of blood and GALT samples.
Ratios of background corrected MFIs for captured Ig and bound antigen (Ag) in Ig*MV*
positions were used to calculate relative affinities (Ag/Ig) of HIV- 1 BaL MV reactive spots
identified in the analysis of blood (o), colon (A) and small bowel (0) samples from HIV-1
negatives, controllers and progressors (in order).
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Table A.5: Summary of heavy and light chain gene usage for HIV-1 BaL Env-specific clones
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Figure A.5: Distribution of VH genes in HIV-1 Env-specific clones in each compartment
Following the analysis of heavy chain sequences for Env-specific clones with IMGT/HighV-
quest software, frequencies of the different VH genes rearranged into antigen-specific antibodies
were enumerated with IgAT software package. 33 unique clones were considered from the blood,
85 clones from the colon, and 90 clones from the small bowel.
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Figure A.6: Distribution of DH genes in HIV-1 Env-specific clones in each compartment
Following the analysis of heavy chain sequences for Env-specific clones with IMGT/HighV-
quest software, frequencies of the different DH genes rearranged into antigen-specific antibodies
were enumerated with IgAT software package. 33 unique clones were considered from the blood,
85 clones from the colon, and 90 clones from the small bowel.
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Figure A.7: Distribution of JH genes in HIV-1 Env-specific clones in each compartment
Following the analysis of heavy chain sequences for Env-specific clones with IMGT/HighV-
quest software, frequencies of the different JH genes rearranged into antigen-specific antibodies
were enumerated with IgAT software package. 33 unique clones were considered from the blood,
85 clones from the colon, and 90 clones from the small bowel.
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Figure A.8: Distribution of CDR3 lengths for heavy chains of HIV-1 Env-specific clones in
each compartment
CDR3 lengths of heavy chains were compared for unique clones recovered from the blood and
GALT of the HIV-infected subjects analyzed. The median lengths were determined to be 42, 45
and 42 nucleotides in the blood (n = 33), colon (n = 85) and small bowel (n = 90), respectively.
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Table A.6: Neutralization IC5 o (pg/mL) measurements for tested antibodies
TIER 1 2 11 12 2
CLADE B B B B C A
VIRUS HxB2 JRCSF SF162 89.6 931N905 92RW020
MIT 41 1.473 171 25 $
MIT 44
MIT 45
2G12 2.664
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Table A.7: Summary of heavy and light chain gene usage for WNV E-specific clones
165
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Clone PaDn V Region D Region J Region Ra % CDR3 V Region J Region Ra() CDR3
MIT 86 100041 IGHV2-26*01 IH32*1 IGHJ4*02 0.0 CARVNSSGYYFDYW IGKV1D-33*01 IGKJ4*01 0.4 CQQYDNLPL TF
MIT 88 110038 IGH4V3-64*05 IGHD3-3*01 IGJ*2 2.9 CVKDLTGAIFGVISELAVW IGKVID-12*01 IGKJ4*01 4.5 QASPT
MIT 96 100038 1IGHVI-2*02 I GHD6-19*01 IIGHJ6*02 0.3 CARGPPPYYYYGMDVW IGLV9-49*01 IGLJ3*02 0.0 CGADHGSGSNFV*PE#VF
C0
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0
Refers to mismatches in FWR1, CDR1, FWR2, CDR2 and FWR3
Antibodies highlighted in green were antigen specific.
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